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ABSTRACT

Tumorigenesis is a multifaceted set of events consisting of the deregulation of
several cell-autonomous and tissue microenvironmental processes that ultimately leads
to the acquisition of malignant disease. Transforming growth factor beta (TGFß) and its
family members are regulatory cytokines that function to ensure proper organismal
development and the maintenance of homeostasis by controlling cellular differentiation,
proliferation, adhesion, and survival, as well as by modulating components of the
cellular microenvironment and immune system. The pleiotropic control by TGFß of
these cell intrinsic and extrinsic factors is intimately linked to the prevention of tumor
formation, the specifics of which are dependent on the various cellular and/or molecular
signaling contexts that exist for TGFß. The diverse roles and the various levels of signal
control for TGFß lend themselves to certain characteristics that are more advantageous
for cancers to usurp in order to promote tumorigenesis, while other anti-tumorigenic
roles for TGFß are more beneficial to tumor development if they are circumvented or
disabled.
Transforming growth factor ß1 (TGF-ß1) exerts its anti-tumor effects in large part
by potently inhibiting cell cycle progression at any point in G1 phase to control the
proliferation of a variety of cell lineages. Loss of sensitivity to TGF-ß1-induced cell cycle
arrest is a crucial event during early tumorigenesis. Indeed, cancer cells of almost all
vi

tumor types display insensitivity to TGF-ß1 inhibition. As such, the pursuit of the
molecular details underlying the TGF-ß1 growth arrest pathway is important for our
understanding of cell cycle regulation, and significantly, how disruption of these
mechanisms contributes to TGF-ß1 insensitivity and tumorigenesis.
TGF-ß1 inhibition of the cell cycle in G1 phase has been shown to involve two
main transcriptionally based molecular events, including the induction of cyclindependent kinase (CDK) inhibitors and the suppression of the c-Myc protein. Both
mechanisms contribute to the maintenance of the retinoblastoma (Rb) protein in its
hypophosphorylated and antiproliferative form, thus preventing progression through the
cell cycle. However, this type of regulation does not offer answers to all of the questions
regarding TGF-ß1 arrest. While these transcriptional mechanisms provide explanations
for TGF-ß1 arrest throughout most of G1, inhibition late in G1 by TGF-ß1 however, does
not require any acute regulation of transcription. In addition, the chance to utilize
canonical TGF-ß1 arrest mechanisms at this time has already passed (i.e. Rb is already
hyperphosphorylated by late-G1). Previous work from our group shows instead that
late-G1 TGF-ß1 cell cycle arrest requires an intact direct interaction between the Nterminus of Rb (RbN) and the C terminus of Mcm7, a subunit of the Cdc45-MCM-GINS
(CMG) replicative helicase. Our studies show that TGF-ß1 exposure in late-G1 prevents
the disassociation of Rb with fully assembled helicases, which remain inactive. In
addition, it was found that early-G1 treatment with TGF-ß1 also targets CMG
components, namely MCM protein accumulation (and therefore hexamer formation) in
G1 is blocked. However, the residue(s) of RbN involved as well as the molecular
mechanisms Rb utilizes for late-G1 TGF-ß1 arrest are not described, nor is it evident
vii

from this work if TGF-ß1 affects other genes involved in CMG assembly and/or
activation. In the following study we explore these unanswered questions for TGF-ß1
growth arrest as a means to understand novel aspects of cell cycle regulation that must
be abrogated during tumorigenesis. Our hypothesis is that CMG helicase control on
some level is critical for all TGF-ß1-induced inhibition of cell cycle progression
throughout the entire G1 phase.
In Chapter 2 herein we have investigated the details and mechanistic
implications of the Rb/RbN inhibitory-interaction with the CMG helicase that is required
for late-G1 TGF-ß1 arrest. We show that N-terminal exons of Rb that are lost in partially
penetrant hereditary retinoblastomas inhibit DNA replication and elongation using a
bipartite mechanism. Specifically, Rb exon 7 is necessary and sufficient to inhibit CMG
helicase activation, while an independent loop domain within RbN that forms a
projection blocks DNA polymerase α (Pol-α) and Ctf4 recruitment without affecting
polymerases δ and ε or the CMG helicase. Individual disruption of exon 7 or the
projection in RbN or Rb, as occurs in inherited cancers, partially impairs the ability of
Rb/RbN to inhibit DNA replication and block G1-S cell cycle transit. Importantly, their
combined loss abolishes these functions of Rb. Thus, TGF-ß1 cell cycle arrest in lateG1 requires the growth suppressive role of Rb in which replicative complexes are
blocked directly via independent and additive N-terminal domains. TGF-ß1-induced
arrest in late-G1 also requires the presence of Smad3 and Smad4, suggesting that a
novel transcription-independent role may exist for Smad signaling proteins in blocking
cell cycle transit directly in Rb-CMG inhibitory complexes.
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TGF-ß1 is thought to require a functional Rb protein to inhibit the cell cycle at any
point in G1 phase. Intriguingly, while cells lacking Rb (and the inhibitory N-terminal
domains) lose sensitivity to TGF-ß1 arrest in late-G1, these same cells remain sensitive
to TGF-ß1 inhibition in early-G1. This Rb-independent TGF-ß1 growth arrest also
occurs in the absence of c-Myc and MCM suppression, as well as without CyclinE-Cdk2
inhibition, but requires Smad3 and Smad4 respectively. Here (Chapter 3) we have
identified the mechanism by which TGF-ß1 achieves Smad-dependent G1 arrest in the
absence of these common mediators. TGF-ß1 inhibits the assembly of CMG replicative
helicases by suppressing the recruitment of the MCM complex to chromatin.
Accordingly, the entire heterohexamer fails to load onto DNA. Cdc6 phosphorylation in
its amino terminus is known to be required for Cdt1-dependent loading of the MCM
complex. We show that in Rb-lacking cells early-G1 TGF-ß1 treatment blocks the
phosphorylation of Cdc6 at serine 54, without affecting total Cdc6 protein levels, to
prevent MCM heterohexamer formation on DNA. Consistent with TGF-ß1 signals
targeting this recruitment and loading step, Cdt1 overexpression promotes S-phase
entry in the presence of TGF-ß1, circumventing the need for Cdc6 phosphorylation.
Importantly, Cdt1 requires an intact C-terminal MCM-binding domain in order to
overcome this TGF-ß1-induced cell cycle arrest mechanism. These data indicate that
early-G1 TGF-ß1 arrest can occur by perturbing Cdc6 phosphorylation to block Cdt1mediated MCM recruitment and loading, leading to inhibition of CMG assembly and Sphase entry despite the lack of Rb and normal c-Myc and CyclinE-Cdk2 activities.
We conclude that the main event governing TGF-ß1-induced cell cycle arrest at
any point in G1 is the inhibition of the assembly and/or activation of the replicative CMG
ix

helicase. However, TGF-ß1 growth arrest has a temporal dependence on the presence
of the Rb protein. In normal cells containing Rb, the accumulation of MCM subunit
proteins is blocked by TGF-ß1 in early-G1 and accordingly MCM heterohexamers are
unable to form. However, if cells are allowed to transit to late-G1 when MCM complexes
have already assembled on origins, but before functional CMG helicases have formed
at G1-S, exposure to TGF-ß1 signaling prevents CMG activation via interactions with
critical inhibitory domains within RbN. Cells lacking Rb (and these residues) are not
sensitive to TGF-ß1 in late-G1. Surprisingly, these cells remain sensitive to TGF-ß1
early in G1 phase despite a lack of c-Myc/MCM protein suppression and CyclinE-Cdk2
inhibition. In these cells the recruitment and loading of the MCM complex is blocked to
facilitate a TGF-ß1-mediated G1 arrest. It is only when this mechanism is overcome by
Cdt1 overexpression that TGF-ß1 is unable to elicit cell cycle arrest in these cells.
These data provide molecular explanations for studies reporting instances of TGF-ß1
arrest without canonical effectors, such as Rb, c-Myc loss, or CDK inhibitors.
Additionally, this work argues for the development of novel cancer therapeutics
targeting CMG helicase assembly or activation, the regulation of which is likely lost in a
variety of TGF-ß1-insensitive and/or Rb-deficient malignancies. Indeed, reintroduction
of these tumor suppressive pathways has shown efficacy in blocking growth of tumors
or cancer cells lacking the same mechanisms. Our studies of Rb/RbN inhibition of DNA
replication also provide proof of principle for this type of therapy, as well as the
framework for how the CMG might be targeted by exploring further and perhaps
mimicking Rb exon7-mediated CMG inhibition biochemically.
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CHAPTER ONE:
BACKGROUND AND INTRODUCTION

Cancer

The collection of over 100 separate diseases known as cancer are perversely
linked to the human pursuit for longevity of life [1]. The largest risk factor for cancer
overall is aging, as the median age of diagnosis is 66 (National Cancer Institute 2016).
In other words, half the cancers that are diagnosed are not identified until the average
individual has lived 80% of their life. Studies have suggested this relationship can be
explained by a tendency for cellular and microenvironmental homeostasis (and a lack of
oncogenic somatic mutations) to be maintained and selected for at higher rates during
the earlier and more reproductively fit years within an average lifespan [3]. Despite the
skew in the age of diagnosis, the overall risk of developing a cancer in one’s lifetime is
high. One in two men and one in three women will be diagnosed in their lifetime
(American Cancer Society 2016). At the same time, 9 of the 10 most prevalent cancer
sites that become invasive for both men and women carry a less than 10% survival rate
(American Cancer Society 2016). So, while the last 30 years of cancer research has
developed rapidly due to advancements in technology, cancer remains the second
leading cause of death in the U.S., accounting for 25% of all mortality (American Cancer
1

Society 2016). Although death rates are dropping for some of the most common cancer
types due to better early detection and treatment, there is clearly much more work to be
done and a great need for a deeper understanding of the underlying mechanisms that
are deregulated during tumorigenesis. This will be crucial for the development of novel
therapies or combinations thereof, and will be based on a body of knowledge akin to
understanding the processes that govern life.
The challenge with cancer is that they result from a breakdown in the vast
amount of normal regulatory mechanisms that control cellular proliferation and
homeostasis [1]. Cancer cells have accumulated mutations in their DNA, some of which
are inherited recessively, predisposing an individual to cancer development even more
[4]. These mutations, as well as the microenvironmental conditions that select for them,
allow cancer cells to proliferate beyond their physical limitations, increasing cellular
burden and leaching oxygen and nutrients from adjacent normal tissues. However,
cancer cells can leave their primary sites and metastasize to other tissues of the body,
an event that is responsible for most cancer-associated deaths (American Cancer
Society 2016). In this section, the unifying acquired characteristics of cancer are
discussed. The interplay between many of the mechanisms that underlie these salient
features of cancer makes tumorigenesis one of the most complex problems in human
health.

C-Src, Proto-Oncogenes, and Loss of Proliferative Control
Perhaps the most well described cell-autonomous characteristic of cancer cells is
the ability to self-sustain proliferative signaling and thus, the chance for cellular division
2

and tumor formation [5]. Normal cells are given cues to proliferate by extracellular
growth factors released from surrounding tissues that bind receptors on the cell surface
to transmit growth-promoting signals [5]. This regulation exists to ensure the
maintenance of homeostatic cell numbers for which normal structure of tissues is
required. Cancer cells lose dependence on these outside signals by various means,
fueling uncontrolled growth.
One of the most fascinating and influential stories in the history of RNA tumor
virus or cancer research that paved the way for the elucidation of several genes
deregulated in this process is the discovery of cellular src (c-src), and the development
of the idea of “proto-oncogenes” [6]. In 1911, Peyton Rous, who would eventually win a
Nobel Prize for his work, showed that a virus or a “filterable agent” from cell-free filtrates
of chicken sarcomas was transmittable to other chickens, and later to other avian
species, and that this transmission caused disease in the new hosts [7]. Several strains
of what was later called the Rous sarcoma virus (RSV) had been developed in various
laboratories, some spontaneously from previous strains, which were either defective in
their ability to replicate themselves and/or that lacked a transforming capacity [8, 9]
(Figure 1.1). Assays developed that allowed for the study of the specific effects of these
varying virus particles on a single cell, and other viral mutants that helped differentiate
between ‘subunits’ of viral RNA sequences, led to the discovery of the viral src (v-src)
gene segment of RNA [10-12].

3

Figure 1.1: RSV Strains. Strains of Rous sarcoma virus (yellow stars) that
lacked replicative capacity (middle) or transforming ability (right) helped
determine the viral component in non-defective strains (left), or v-src.

The identification of v-src, a component of the viral RNA that is required for
transformation, but that is dispensable for the replicative potential of the RSV virus,
generated the idea that this gene may have originated from cellular DNA that the viral
4

genome had usurped for transforming purposes. This notion was supported by the idea
of the “oncogene”, genes contained by RNA tumor viruses that when activated could
cause cancer [13]. Indeed, probes specific for src, eventually were shown to hybridize to
the DNA of various avian species, and c-src was identified in more Nobel Prize winning
work [14]. Later studies then show src was a protein kinase, genes that are necessary
for the phosphorylation of various substrates at specific residues leading to the
transmission of signals for various cellular processes, including proliferation [15, 16]. A
key feature of the cellular src gene was that unlike its v-src counterpart, c-src must be
mutated and/or overexpressed to cause transformation, and was therefore termed a
‘proto-oncogene’ [17]. All of these revelations led to a surge in the search for the
substrates of src and how it signals, as well as other proto-oncogenes that have similar
importance for tumorigenesis. These genes when abrogated are the common mediators
of self-sustained proliferation in cancer cells.
There seem to be three main molecular mechanisms to alter the signaling of
oncogenes and their pathways in cancer to overcome the need and maintenance of
normal growth factor stimulation [1]. First, cancer cells may establish what is called
autocrine signaling loops, in which they have become able to produce their own growth
factors which in turn stimulates their own proliferation, such as the production of
platelet-derived growth factor (PDGF) by glioblastomas [18]. Next, the cell surface
receptors that bind growth factors and perpetuate intracellular signals are commonly
overexpressed or become constitutively active via mutation in a number of cancers [18,
19]. Lastly, the intracellular components that relay growth signals in the cell may be
mutated to do so beyond the control of components upstream of them in the pathway.
5

Perhaps the best example is the Ras protein of the MAP kinase pathway, which is
altered in about 25% of human tumors to function in this constitutive manner [20].

Anti-Oncogenes/Tumor Suppressors
As the idea of the oncogene was being developed, so too was the notion that
there were also genes that could counter oncogenic activation as a means of tumor
prevention. These ‘antioncogenes’ or tumor suppressor genes are now known to be
indispensable regulators of normal cellular proliferation and differentiation, and also
function to maintain the genomic integrity via checkpoint mechanisms that act as
sensors of stress, including oncogenic stimulation, to either eliminate faulty/damaged
cells or to halt their proliferation until the such stress is relieved [4]. It is now clear that
the inactivation or abolishment of these growth suppressive mechanisms is a critical
feature of the large majority, if not all, cancers that exist [5]. In addition, other proteins
and extracellular signaling messengers that modulate the activity of these tumor
suppressor genes have also been identified whose perturbation or loss has been
implicated in cancer development [21-26]. Some of these genes and/or the pathways
that govern their function (e.g., Rb and TGFß) will be discussed separately in more
detail in following sections herein, as they are more relevant to the work carried out in
these studies.
Classical tumor suppressor genes share several qualities that define their impact
on tumorigenesis [4]. The first of these traits is their recessive nature, where one allele
is sufficient in most cases to maintain homeostasis, while the loss and/or mutational
inactivation of both alleles in “two-hits” is a common occurrence in tumors [27, 28]. In
6

instances where a single mutant copy of a tumor suppressor is inherited, the
susceptibility to cancer is greater leading to earlier onset of disease on average, as only
one mutation is now needed to completely lose its function. In cancer, commonly the
normal allele is deleted or inactivated by mitotic recombination in a process known as
loss of heterozygosity (LOH) (Figure 1.2) [4]. The identification of genetic loci
susceptible to LOH is a classical means by which to identify candidate tumor
suppressor genes in cancer. Therefore, the increased risk for cancer due to
heterozygous allelic inheritance is another common feature of tumor suppressors.
Lastly, ‘antioncogenes’ are commonly abrogated in a variety of sporadic cancers [4].

Figure 1.2: Loss of Heterozygosity. “Two-hit” hypothesis for tumor suppressor
genes, in which one inactive allele (red X) is inherited in the first stage that
contains a point mutation (yellow star). In the second stage, the functional allele is
lost by deletion or more commonly by mitotic recombination and spontaneous loss
of the functional allele.
.
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Along with the Rb (discussed in the next section), p53 is the best known and
most heavily studied of the tumor suppressor proteins in terms of its importance for
cancer prevention [4]. The TP53 gene was cloned from cells that were transformed with
the polyoma tumor virus simian virus 40 (SV40), and encodes the p53 protein [29]. At
first it was believed that p53 might actually be a collaborative oncogene as it contributed
to Ras-induced transformation of fibroblasts [30], but the true function of a wild-type p53
as a tumor suppressor was eventually demonstrated [31]. The p53 protein is now
understood to act as a sensing mechanism for various forms of cellular stress that
cause DNA damage, thereby guarding genomic integrity and preventing tumor
formation [32].

The Retinoblastoma Protein
Alfred Knudson was responsible for pioneering the aforementioned “two-hit
hypothesis”, as well as defining the other common features of tumor suppression
discussed in the previous section [27]. These seminal concepts were largely developed
by his studies of retinoblastoma incidence, and in particular childhood cases where
heredity was likely playing a role [28]. Later that decade, Knudson and others were able
to identify chromosomal deletions of 13q14 within familial retinoblastomas, hinting at the
fact that the “RB gene” overlapped with this genetic locus [33, 34]. Significantly, it was
later demonstrated that the same RB sequence was also deleted in cases of sporadic
retinoblastoma [35], and was subsequently cloned in 1986 [36].
The Rb protein is now understood to be part of a related family of genes,
consisting also of p107 and p130, whose tumor suppressive function stems from their
8

control over various processes, such as cell cycle progression, apoptosis, and
differentiation [37]. Although Rb is known to associate with over 100 different protein
binding partners [38], the best characterized interactions that mediate a significant
degree of Rb control are its interactions with the E2F family of transcription factors [3941]. These inhibitory interactions repress the E2F-dependent transcription of genes
needed for metabolism, cell cycle progression, and DNA synthesis via the recruitment of
histone deacetylases (HDACs) that modify chromatin and block transcription at these
E2F-responsive promoters [42]. Several of these cell cycle related genes and their
importance for Rb and p53 pathway control are discussed in the “Cell Cycle” section to
follow in Chapter 1.
The cell regulatory functions of Rb, including its repressive interactions with E2F
family members, are largely exerted during G1 phase to block S phase entry [43].
However, Rb is also critical to block the initiation and progression of DNA replication in
S phase, independent of its role in suppressing E2F transcription [44]. In addition, Rbdependent cell cycle arrest in G1 can occur normally in embryonic fibroblasts from mice
endogenously expressing a variant of Rb that is defective for repression of E2F target
genes [45]. The mechanisms by which Rb controls this E2F-independent intra-S phase
checkpoint as well as the nature of other functions of Rb that are separable from E2F
gene suppression are not known. In Chapter 2, we explore the biochemical details of a
direct and physical role of Rb in blocking DNA replication, and provide some of the first
molecular explanations for these unanswered phenomena.
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RbN and Cancer
The various tumor suppressive functions of Rb are mediated in large part by
interactions with its carboxyl terminus (C terminus), which contains a large pocket
domain [46, 47]. As such, mutations of Rb that perturb the C terminal pocket domain are
highly penetrant for inherited cases of cancer [48]. These observations and other in vitro
evidence have led some to assert that the amino terminus of Rb (RbN) might be
dispensable for Rb-mediated cellular control. However, other indications clearly
implicate RbN in Rb-mediated growth and tumor suppression. First, RbN is heavily
conserved throughout the evolution of vertebrates, sharing 33% amino acid identity with
those pRb orthologues [48]. Regulatory phosphorylation sites within RbN are also
conserved among vertebrates and are functional [49]. RbN physical interactions with its
own C terminus are also necessary for certain mechanisms regulating E2F interactions
with the large pocket [50]. RbN also has a role in inhibiting DNA replication requiring
interactions with the replication machinery, which TGF-ß1 utilizes in late-G1 to arrest
cell cycle progression [51, 52]. Additionally, residues of RbN are critical for complete
tumor suppression in mice [53]. Perhaps the most telling is the existence of multiple
deletions of RbN residues that are present in familial retinoblastomas, astrocytomas,
and prostate cancers [54-56]. In these cases, portions of RbN are lost in frame, leaving
a completely intact large pocket domain that can interact with E2F. RbN mutations in
the above transgenic mice, as well as in families inheriting defects in RbN, display
partial penetrance for tumor development. The discrepancy between these RbN
mutations and aberrations within the C terminus of Rb in terms of penetrance, also
suggest that functions of RbN are distinct from those involving its large pocket domain
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and E2F interference (See Figure 1.3 for Rb domain comparisons). In Chapter 2, we
examine the significance of some of the in-frame deletions within RbN and also provide
explanations for their partial penetrance.

Figure 1.3: Retinoblastoma Protein Domains. The large pocket of the
retinoblastoma protein (Rb) in its carboxyl terminus where E2F binds is required
in the majority of in vitro assays assessing Rb transformative ability, and
mutations in this region are highly penetrant. The amino terminus of Rb (RbN) is
also required for full tumor suppression by Rb in vitro and in vivo, and mutations
in RbN are normally partially penetrant.
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Other Unifying Acquired Features of Cancer
In addition to self-sufficient growth and an avoidance of growth suppressive
signals/mechanisms, cancers share several other characteristics that contribute to
tumorigenesis, and make up the remaining “hallmarks of cancer” [5]. These include the
evasion of apoptotic cell death, an induction of angiogenesis, replicative immortality,
increased immune tolerance, the deregulation of cellular energetics, and the ability to
invade other tissues [5]. The acquisition of the characteristics that bind many cancers
together, however, is not a linear and scheduled process. Whereas some events are
sufficient for the development of some tumor types (e.g. Rb loss in retinoblastoma),
others can only develop after many if not all of these traits are attained. The sequence
that these mechanisms for tumorigenesis are acquired may also differ from one tumor
type to another, or within the same type of cancer [1]. Still, the ultimate development of
these phenotypes seems to be shared by many if not all cancers.
Apoptosis, or programmed cell death, is a normal mechanism for maintaining
homeostasis that acts to balance unbalanced regulation of cell proliferation and
architecture [5]. The apoptotic machinery becomes active in response to intracellular
and extracellular stimuli that are sensed by a variety of mechanisms, and ultimately
signal for effector proteins called caspases to carry out the apoptotic program in a
specific order of events [57, 58]. The molecular basis for evading apoptosis and its
relation to cancer development began with the discovery of elevated levels of the antiapoptotic bcl-2 gene in follicular lymphomas [59]. The p53 tumor suppressor protein is
one of the most important regulators of apoptosis, activating cell death in response to
DNA damage, hypoxia, and oncogenic stimulation. The loss of p53 in most human
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tumors also contributes to a failure to elicit these apoptotic responses, leading to the
accumulation of DNA damage [60].
The presence of blood vessels within and around cellular tissues is paramount
for their acquisition of sufficient oxygen and nutrients. Angiogenesis, or the process by
which new blood vessels are formed, limits the growth potential of pre-formed tumors,
where a dependence on these nutrient factors would be increased [61, 62]. Vascular
endothelial growth factor (VEGF) is a common example of extracellular regulatory
signals that govern angiogenic stimulation. The interaction of VEGF with its cognate
receptor tyrosine kinase (RTK) on endothelial cells initiates angiogenic pathways [18].
Blocking the action of VEGF and its influence on neovascularization is sufficient to
inhibit the growth of tumors in mice [63, 64]. These and many other studies suggest that
the promotion of angiogenesis is critical for tumorigenesis in middle to late stages of
tumorigenesis [5].
Limitless replicative potential or immortalization is also an important phenotype
for cancer cells to gain on their path toward malignant disease [5]. Telomeres are long
stretches of repeating elements that compose the ends of chromosomes that are
shortened upon rounds of DNA replication as 3’ DNA ends fail to replicate via
polymerases. This can eventually lead to cellular senescence or cell death associated
with a crisis state of karyotypic disarray [65]. In almost every type of malignancy, cancer
cells have escaped these limiting mechanisms, and adopted stable maintenance of their
telomeric sequences, despite their increased proliferative state [66]. The telomerase
enzyme, which is suppressed in normal human cells, is responsible for the stability of
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telomeres in cancer cells. It functions to elongate telomeric DNA sequences by the
addition of six bp (base pair) nucleotide repeats [67].
Another facet of tumorigenesis that is a requisite for the development of a cancer
is circumventing, limiting, and/or adulterating normal functions of the immune system
that are constantly working to prevent neoplastic growth [5]. This dependence is
evidenced in many forms, including the observation that the incidence of many cancers
in immunocompromised individuals is much greater [68]. In addition, mice that are
deficient in various cellular components of innate and adaptive immunity, including
CD8+/CD4+ T cells and NK (natural killer) cells, all demonstrate large increases in tumor
incidence [69]. Immune surveillance mechanisms therefore, are constantly working to
eliminate immunogenic cancer cells. Cancer cells can also modulate components of the
microenvironment to dampen immunogenic responses. TGFß secretion by cancer cells,
for example, provides an immunosuppressive function against T lymphocytes and NK
cells [70]. In addition, cancer cells can recruit other immune cells that act to balance
inflammatory responses such as regulatory T cells and myeloid-derived suppressor
cells [5]. These revelations and others have led to the advent of new “immunotherapies”
for cancer that reestablish immunogenic responses to tumors chemotherapeutically or
that involve “cellular treatment”, in which tumor-derived cells specific for killing are
expanded or modified, and turned back against their tumors of origin.
Another switch that cancer cells undergo during tumorigenesis is a dependence
on the glycolytic metabolic pathway for energy production, in which glucose is
processed into pyruvate. This increases the need for glucose uptake by cancer cells, as
glycolysis is far less efficient in terms of ATP production [5]. This “Warburg-effect” is
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exacerbated by limited oxygen conditions for the tumor, or hypoxia [71]. Oncogenes
such as Ras and c-Myc are also capable of contributing to this dependence on
glycolysis [72]. This observation has also fueled the idea that this metabolic
reprogramming is just a consequence of oncogenic stimulation, rather than a necessary
quality to perpetuate tumorigenesis. Still others believe that an increase in the presence
of biochemical intermediates of the glycolytic pathway are important for the biosynthesis
of nucleosides and amino acids that are in higher demand as cancer cells proliferate
[73].
As was mentioned in previous sections, the mortality rates associated with the
most prevalent cancers are highest when the tumor has left its primary site of origin,
and infiltrated other tissues in processes known as invasion and metastasis [5]. One
step that is important for these deadly characteristics is the deregulation of mediators of
cell-to-cell interactions, such as immunoglobulin and E-cadherin that are expressed on
the surfaces of epithelial cells. This gene and the cytoplasmic effector of its antigrowth
signals are commonly lost or their function mutated in epithelial cancers [74]. In keeping
with normal cellular functions being adulterated by cancer cells, a program of epithelialto-mesenchymal transition (EMT) that is akin to processes involved in embryonic
development and wound healing. The loss of adherent junctions, altered morphology,
and the degradation of the extracellular matrix are processes all associated with EMT
that act to increase invasive potential [5]. TGFß can also facilitate an EMT program in
vivo and in vitro, which will be discussed in greater detail in “The TGFß Superfamily”
section of Chapter 1 below.
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The Cell Cycle

The previous sections outlining the plethora of regulations that must be
overcome for tumorigenesis to occur details both cell autonomous and/or
microenvironmental processes that support unbridled growth, and explains how other
normal mechanisms regulating development, wound healing, or metabolic stress
responses can be usurped by tumors to advance malignancy. However, inherent to the
formation of tumors of all types is the deregulation of the processes that control the
decision to enter and reenter the cell cycle. The cell cycle is a highly regulated process
that involves a coordinated series of steps, the main purposes of which are to prepare
the entire genome for duplication, replicate the genome without making any errors, and
disseminating one copy each to the two new daughter cells [75]. Most of the cells of the
body however, are terminally differentiated and not proliferating or actively traversing
the cell cycle. This state of exclusion from the cell cycle, in either quiescent or
senescent forms, is termed G0. If able (i.e. the telomeric state allows) and if it is needed
cells may reenter the cell cycle upon mitogenic stimulation (and relief from anti-growth
signals, such as TGFß) [75]. While cells that are normally highly proliferative, such as
the gut epithelium or tumor cells spend much of their time actively cycling. In either
case, there are a series of distinct stages that make up the cell cycle, with various
checkpoint mechanisms along the way that ensure accurate DNA replication and
passage of genetic material to daughter cells. These phases are the Gap phase 1 (G1),
synthesis phase (S), gap phase 2 (G2), and mitosis (M) (Figure 1.4).
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Figure 1.4: The Cell Cycle. Stages of the mammalian cell cycle, consisting of
G1 in which replication machinery assemble on DNA, followed by DNA
replication in S. G2 phase is followed by M phase when daughter cells are
formed. Normal cells typically enter the cell cycle from a quiescent state (G0)
upon growth factor stimulation.
The G1 phase is important for the maintenance of genomic integrity as the
cellular decision to begin replicating the genome in S phase is made in G1. Several
events occur during G1 that provide the supplies and tools necessary to carry out
accurate DNA replication. Yet other necessary events for cell cycle progression occur in
G1, in which negative regulation of S phase entry is relieved [76]. It is also within G1
phase that a “point of no return” has been defined. Termed the restriction point (R
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Point), this period late in G1 phase was identified as the time after which a cell was no
longer dependent on growth-promoting signals to enter S phase and complete the cell
cycle [77]. However, it is now understood that regulation may still occur after the R point
to prevent S phase entry, such as by anti-growth signals like TGFß [52]. In S phase, the
genome is replicated and therefore a doubling of DNA content is evident by the end of S
phase. G2 phase begins with the completion of new DNA synthesis, and is
characterized by further growth as the cell prepares to divide. The final mitotic phase
exists to organize the newly synthesized DNA into condensed chromosomes and to
ensure equal distribution of this genomic information to each new cell.
The precise coordination of these cell cycle events is controlled in large part by
genes known as cyclin-dependent kinases (CDKs), which phosphorylate a number of
proteins to either activate or inhibit their function, and to promote cell cycle progression
[78]. While the CDKs remain stable throughout much of the cell cycle, their activation is
modulated by one of two main mechanisms. First, proteins called cyclins must complex
with CDKs to facilitate their activation. The cyclins are variably expressed at different
stages of the cell cycle coordinating the activity of their CDK partners at the “correct”
time [78]. For example, the D and E/A type cyclins regulate the activity of CDK4/6 and
CDK2 in G1 phase, respectively, whereas, other cyclins modulate activity of CDKs in
G2-M, such as cyclinB-Cdc2 complexes [79, 80]. The cyclins were discovered in many
cases as the search expanded for mammalian counterparts to cyclin-like proteins in
yeast. For example, cyclin D1 or CCND1 was identified when it was able to complement
a deficiency of CLN proteins in budding yeast (Saccharomyces cerevisiae) [81]. The
other common regulation of CDK activity is by the CDK-activating kinase (CAK) enzyme
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complex (of yet more cyclins and CDKs), which acts as a kinase and phosphorylates
residues on various CDKs to facilitate their activation. The threonine 160 residue of
CDK2, for instance, is phosphorylated by CAK and is required for CDK2 activity [82]. In
addition, extracellular signals via Ras and PI3-K are known to regulate the transcription
of cyclins and their assembly with CDK complexes [83].
The activation of checkpoint mechanisms in response to various aberrations that
can arise during the cell cycle are crucial for maintaining genomic stability [84].
Modulating the activity of cyclin-CDK complexes is one of the main mechanisms
underlying checkpoint control, and a breakdown of these regulations are highly
associated with increased cancer incidence [85, 86]. The p53 protein, for instance, is
activated in response to DNA damage or hypoxia in G1 or S phase to halt cell cycle,
and in many instances lead to apoptosis [87]. Another such checkpoint is governed by
the Rb tumor suppressor gene in G1, and like many checkpoint pathways, depends on
the activity of specific cyclin-dependent kinase inhibitors (CDKi) that inactivate or
prevent the activation of CDKs [88]. As was discussed in previous sections, Rb
suppresses the activity of the E2F family of transcription factors. E2Fs are responsible
for inducing many genes needed for cell cycle activity, including thymidine kinase,
dihydrofolate reductase, c-myc, cdc2, as well as cyclins required for mid-late G1
progression, such as cyclin E and A [89, 90]. CyclinD-CDK4/6, and then cyclinE-CDK2
complexes, act progressively to phosphorylate Rb, regulating its tumor suppressive
activities [37]. Although it is not precisely understood which phosphorylation sites of Rb
(or combinations therein) control any one function of Rb, the net result of a
hyperphosphorylated Rb molecule is E2F-dependent transcription and progression into
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S phase. However, sensors like p53 or extracellular anti-growth signals (e.g. TGFß,
discussed in more detail in “The TGFß Superfamily” section to follow) can prevent CDKdependent Rb phosphorylation by activating CDKi [88]. Members of the Cip/Kip (e.g.
p27Kip1 and p21Cip1) and Ink4 (e.g. p16INK4a) families of CDKi function to inhibit the
activity of CDK2 and CDK4/6 activity, respectively, which retains Rb in a
hypophosphorylated and E2F-inhibitory state [91]. In addition, Rb mediates an intra-S
phase checkpoint, where in response to radiation Rb must be present and
dephosphorylated to associate with and block elongation of replication [92]. However,
levels of phosphorylation may be permissive to other growth-suppressive functions for
Rb later in G1, before a cell has traversed into S [52].
The proper regulation of this Rb network is critical for the prevention of tumor
formation, and defects in various components of this pathway are evident in many, if not
all cancer, however seem to be mutually exclusive among tumors [37]. D-type and Etype cyclins are overexpressed in breast cancer and mantle cell lymphoma and their
deregulation is correlated with negative prognostic outcomes, while CDK4 is elevated in
a large portion of glioblastomas [37, 93, 94]. The deregulation of the cyclin E oncogene
in mouse fibroblasts causes several chromosomal losses/gains, as well as aneuploidy
[95]. One explanation for the genomic instability observed upon cyclin E overexpression
is that the association of elements of the replication machinery and DNA is blocked [96].
Additional CDK-associated effects on the coordination of DNA replication will be
discussed in the next section, “DNA Replication”. Also, the p16INK4a CDKi is now
considered a tumor suppressor gene, as its mutational inactivation or loss is noted in
many forms of cancer, including melanoma and pancreatic cancer [97]. Therefore,
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targeting the CDK pathway to reestablish Rb-mediated tumor suppression as a cancer
therapy has been of interest for many years. The FDA approved Palbociclib is a specific
CDK4/6 inhibitor, and has shown great clinical efficacy in treating breast cancers when
used in combination with other inhibitors that block the production of estrogen. This
therapeutic approach is likely to be extended to other cancers in which these pathways
are deregulated [98].

DNA Replication

The coordinated events of the cell cycle are linked tightly to those that comprise
the assembly, initiation, and elongation of DNA replication. The duplication of all three
billion base pairs of DNA in S phase once and only once per cell cycle, and the precise
initiation of this process at the right time (i.e. G1-S transition) is absolutely critical for the
maintenance of the genome. Astoundingly, by using purified proteins to recapitulate
replication in the absence of a cell or cell extract the minimum complement of genes
required for eukaryotic DNA replication has been identified [99]. Deregulation or errors
in replication or elements of the cell cycle that directly regulate replication dynamics that
are not properly managed by checkpoint mechanisms, such as those lost in many
cancers, can perpetuate genomic instability, a key enabling characteristic for cancer [5,
95]. As such, positive and negative extracellular signals that regulate entry into the cell
cycle also depend upon precise manipulation of the replication machinery [52]. In
Chapters 2 and 3, we provide data that indicate the antiproliferative signals of TGF-ß1
in G1 phase ultimately rely on inhibiting the assembly and/or activation of the replicative
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DNA helicase. The following sections in “DNA Replication” summarize the genes
involved in the normal progression of these processes, as well as important aspects of
their regulation that prevent genomic instability and tumorigenesis.

Origins of Replication
Origins of replication, or the sites where DNA replication is initiated, become
more and more complex and variable through the evolutionary progression from
prokaryotic systems to eukaryotic and the metazoans [100, 101]. In prokaryotes,
replication initiates on a circular chromosome at a well-described origin, however
eukaryotic origins contain much more variation between model organisms [100, 102].
Although major differences exist within the eukaryotes as to where replication will
initiate, the complex of proteins that mark origins of replication known as the origin
recognition complex (ORC) is highly conserved from yeast to humans [102]. For
example, variation in sequence specificity exists even between unicellular yeast model
organisms, but ORC binding to origins is required for initiation in both cases. The origins
of the budding yeast S. cerevisiae are smaller and contain 11 bp autonomously
replicating sequences (ARS) known as the ARS consensus sequence (ACS), which is
crucial for initiation of replication [103]. In the presence of ATP, ORC binds the ACS to
mark origins [104]. Schizosaccharomyces pombe (S. pombe), the fission yeast, have
larger origins of up to one kilo base pairs (kb), and contain more elements that control
their activity. These origins consist of asymmetrical AT sequence stretches of 20-50 bp
that can artificially rescue deficient origin activity observed in their absence [102, 105],
and ORC binding can occur in multiple fragments of the origin [106].
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In the multicellular metazoans there is very little, if any, sequence specificity at
origins that define ORC binding and initiation. In Drosophila melanogaster, studies of
the chorion gene locus have revealed several components required for ORC recognition
and initiation in this system. The chorion origin is large and contains various elements
required for its amplification, including the 440 bp amplification control element (ACE)
and an amplification-enhancing element (AER or AER-d), which direct ORC recruitment
and initiation events [100, 107]. Mammalian origins of replication are even less well
defined, and initiation events can occur from it seems any DNA sequence. Indeed,
studies of the Chinese hamster ovary (CHO) DHFR locus have shown that broad
initiation zones exist in a large 55 kb intergenic region [108]. This dynamic is also
evident at other metazoan loci. This illustrates a trend where the potential for many
initiation sites is maintained, but where only one or two will be used to amplify a given
DNA region [102]. A given stretch of DNA whose replication depends on a single origin
to initiate is known as a replicon [109]. In Xenopus laevis embryonic extracts replicons,
replicons appear to be 9-15 kb, while mammalian replicons such as those in CHO cells,
are replicated in clusters that are more widely spaced at 50-500 kb averaging at 100 kb
[110, 111]. Therefore, while sequences dictating origins of replication are not distinct in
metazoans, the ability to fully assemble the protein complexes required for bi-directional
replication at origins instead seem to limit their function. This control is exerted in two
main steps, one involving the assembly of uninitiated complexes at origins, and the
second involving the coordinated initiation at “chosen” origins.
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The Pre-Replication Complex and Licensing
In eukaryotes, the assembly of an inactive pre-replication complex (pre-RC)
precedes the initiation of DNA replication at origins [102]. The members of the pre-RC
are heavily conserved from yeasts to human, and perform almost identical functions,
however the mechanisms restricting their assembly at origins in a process termed
“licensing” vary slightly between yeasts and the metazoans [112, 113]. In actively
cycling cells (or tumor cells), the pre-RC is formed in late M and early G1 phase,
whereas in cells entering the cell cycle from quiescence, as is the case for most cells of
the body, pre-RC assembly is completed in mid-late G1 phase [114-116]. The licensing
of pre-RCs in eukaryotes depends both upon the activity cell cycle components like
CDKs (although this dependency can vary) and the availability of various components of
the pre-RC that are required for its successful loading onto DNA [113].
The pre-RC (Figure 1.5) assembles in a step-wise fashion. First, as was
discussed previously, ORC complexes bind to origins of replication with varying
dynamics depending on evolutionary complexity [100]. ORC is composed of the Orc
proteins 1-6 that were found in yeast based on their recognition of ARS elements via the
ACS at origins [117]. Several of the Orc proteins are members of the AAA+ family of
ATPases that are associated with a wide range of cellular activities. The binding of ATP
facilitates the association of ORC with DNA [118], and subsequent ATP hydrolysis by
ORC is required for successive loading of pre-RCs [119].
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Figure 1.5: Pre-RC Assembly and the CMG Helicase. ORC-Cdc6 direct the
loading of a Cdt1-MCM complex onto DNA (OCCM complex). Pre-RC formation
occurs by late G1, upon Cdc6 and Cdt1 release, and at the G1-S transition the
recruitment of Cdc45 and GINS to MCM complexes for an active CMG helicase.

Next, the concerted function of both cell division cycle 6 (Cdc6) and cell division
cycle 10-dependent transcript 1 (Cdt1) are needed to load the two mini-chromosomal
maintenance (MCM) complexes, consisting of Mcm subunits 2-7, onto DNA and to
complete the licensing reaction [120]. Cdc6 is another AAA+ ATPase that was initially
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found in S. cerevisiae to be essential for MCM loading [121]. The ORC-Cdc6 complex
and its various ATPase domains organize in a circular manner that is similar to the
clamp-loading machine found in prokaryotes and eukaryotes, and the sequential
hydrolysis of ATP by each are important for loading of Mcm2-7 [122-124]. The “clamp”
that Cdc6 facilitates the loading of in this case is Cdt1 pre-bound to the MCM
heterohexamer [125]. Cdt1 was found in fission yeast as a crucial transcriptional target
of cdc10, and mutations in Cdt1 result in inhibition of DNA replication and checkpoint
errors in S phase [126]. While Cdt1 does not seem to have enzymatic activity of its own,
it appears to act as a scaffolding protein that recognizes DNA-ORC-Cdc6 complexes
and alters MCM conformation in a way that is conducive to their loading onto DNA [127129]. Cdt1-mediated decondensation of higher order chromatin structure is also known
to be crucial for its role in MCM recruitment [130]. The mechanism for loading MCMs is
not fully understood, but is thought to involve a dynamic gate between Mcm2 and Mcm5
that may be opened to allow MCM complexes to dock onto DNA [131, 132]. Consistent
with Cdt1 also influencing this gate and autoinhibitory functions of Mcm6, its interaction
with MCM mainly involves binding with Mcm2, 5, and 6. The formation of the
intermediate containing ORC, Cdc6, Cdt1, and the MCM hexamer is known as the
OCCM complex [133, 134]. After the loading of one MCM hexamer, Cdc6 and Cdt1 are
released, yielding a tightly loaded MCM hexamer on DNA [134]. This is followed by a
similar, yet more delayed program to load a second MCM hexamer antiparallel to the
first. Hexamers are arranged with head-to-head contact of their amino terminal
domains, which leaves the MCM carboxyl termini facing away from each other, in a
manner that supports bi-directional fork elongation [135]. The MCM double-hexamer is
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now poised and ready for activation at origins to support DNA synthesis in S phase.
As their name implies, the MCMs were identified while assessing S. cerevisiae
mutants defective in the maintenance of circular minichromosomes [136]. The
conservation of the MCMs suggested long ago that the hexameric formation had
homology to DNA helicases, and Mcm2-7 do demonstrate helicase activity in vitro [137].
While limited, Mcm2-7 and various sub-complexes of MCMs indeed have also shown in
vitro helicase activity, for example a purified complex contacting just Mcm4, Mcm6, and
Mcm7 [138]. However, the entirety of the MCM hexamer is needed for pre-RC formation
in Xenopus extracts, as well as the viability of S. cerevisiae [139, 140]. Additionally,
significant helicase activity and origin initiation requires the association of additional
factors at G1-S (discussed in the next section) [141]. As was alluded to previously, the
licensing of pre-RCs to support DNA replication of the entire genome only once per cell
cycle is critical for preventing re-replication of regions of previously synthesized DNA
and for preventing genomic instability and tumor formation [113, 142]. MCM loading
dynamics are at the heart of this process.
While similarities exist, there are distinct differences between the programs that
control licensing in yeast and in metazoans. The licensing of MCM complexes in yeast
largely depends upon the activity of CDKs. High activity of CDK is inhibitory for licensing
and persists in late S phase and through G2 and mitosis. However, at low levels of CDK
activity in mid to late-G1 the loading of MCM complexes is permissive [113]. In
metazoans, the licensing program and its CDK regulation is more complicated. Rather
than CDK activity, the factor that seems most important for metazoan licensing is the
availability of Cdt1. Studies have shown that at least some Cdc6 is regulated by CDK27

dependent phosphorylation, and is exported from nucleus in S phase to prevent relicensing, but other reports suggest that it is still not clear how significant this
mechanism is to prevent re-replication in vivo [143-145]. Cdc6 phosphorylation is also
known to play a protective role for its stability. Phosphorylation of N-terminal residues of
Cdc6 blocks its association with the APC/C ubiquitin ligase, which stabilizes the Cdc6
and facilitates the loading of MCM [146]. Therefore, while CDK-dependent
phosphorylation of Cdc6 may be inhibitory for MCM loading, some permissible level of
Cdc6 phosphorylation is needed to successfully license DNA. The sites being
phosphorylated and the timing of these events seem crucial for these differences, but
are not fully understood [147]. In addition, the regulation of Cdt1 activity by various
mechanisms is crucial for the prevention of re-replication. A protein called geminin,
which is downregulated in late M phase, binds to Cdt1 and inhibits its activity [148]. The
importance of this mechanism for the regulation of licensing is clear, as a loss of
geminin can lead to significant re-replication [149]. Geminin is stabilized beginning in
late G1 and early S phase and regains its control over Cdt1 to prevent re-replication. In
addition, Cdt1 stability and therefore its activity, is modulated by proteolytic pathways
involving complexes of Cullin-class ubiquitin ligases, such as CRL4-Cdt2 and CRL1Skp2 [113].

CMG Helicase Assembly/Activation and DNA Synthesis
The amount of MCMs loaded onto DNA during the licensing program far
outnumbers the quantity of hexamers that are needed to replicate a given region of
DNA. This phenomenon contributes to what is known as the “MCM paradox”, in which
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the majority of MCMs are not found localized with active replication forks [150]. It was
found that these residual dormant MCM complexes are crucial to complete S phase,
and are activated in response to replicative stress [151, 152]. The manner in which
these MCMs are “chosen” to initiate DNA replication is far less understood, although
there seems to be a role for the c-myc oncoprotein in this process [153]. Minimally for
an MCM complex to become an active helicase, the recruitment of two additional factors
at G1-S is required; Cdc45 (cell division control protein 45) and the GINS four-subunit
complex (‘Go, Ichii Ni San’; and ‘5, 1, 2, 3’ in Japanese) [141, 154]. This complex
containing Cdc45-MCM-GINS has thus become known as the CMG DNA helicase
(Figure 1.5). Both the function of a conserved Treslin/RecQL4/TopBP1 complex and the
kinase activity of CyclinA-CDK2 and Dbf4-Cdc7 act to promote CMG assembly and
activation at the G1-S transition, and a bi-directional replication fork is initiated [120,
155]. The recruitment of polymerase α/primase, pol-ε and pol-δ allows for DNA to be
synthesized in the 5’ to 3’ direction on both the leading and lagging strands [156]. As
single stranded DNA is formed and then replicated the formation of aberrant secondary
structures is prevented by replication protein A, or RPA [157]. The CMG helicase is
functionally linked to the polymerases during elongation of DNA replication via the
cohesion factor Ctf4. Specifically, Ctf4 is responsible for maintaining pol-α interactions
with the CMG, and also plays a role in stimulating polymerase activity [158-160]. This
dynamic complex of DNA, the CMG helicase, and polymerases are known as the
replisome progression complex (RPC).
It has been shown that the presence of Cdc45 is necessary for DNA replication in
Xenpous extracts and S. Pombe yeast [161-163], and the human homolog was also
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found [164]. In mammalian cells, precise quantification of pre-RC subunit stoichiometry
using purified protein standards revealed that Cdc45 is extremely rate limiting for
replication for the average replicon [111]. The average mammalian replicon of 100 kb
was shown to contain one ORC hexamer, two Cdc6 molecules, four to five MCM
hexamers, and just 0.35 molecules of Cdc45. The amount of Cdc45 molecules available
on chromatin is even fewer, with two molecules for 1400 kb of DNA [111]. As Cdc45 is
very stable throughout the cell cycle (i.e. Cdc45 is reutilized from replicon to replicon),
its low availability is an explanation for the increased size of mammalian replicons
compared to Xenopus, where Cdc45 is much more abundant [111]. By microinjecting
additional Cdc45 into nuclei of cells in S phase, dormant MCM complexes are activated
resulting in a three-fold increase in replication foci [111]. Thus, the proper association of
Cdc45 with MCMs is crucial for DNA replication and dictating its progression. The GINS
complex, composed of Sld5, Psf1, Psf2, and Psf3, functions to stabilize interactions
between Cdc45 and the MCM complex in RPCs during replication [165]. Mcm10, is
another protein that was identified as being required for DNA replication in S.
cerevisiae, and is also required for the association of Cdc45 with pre-RC complexes, as
well as pol-α retention at replisomes [166, 167]. The exact mechanisms by which Cdc45
influences helicase activation is less understood, but recent evidence suggests that
interactions between Cdc45 and the leading strand are important for helicase activity,
guarding against leading strand slippage as the CMG adopts more open confirmations
[168]. In the next section, a family of pleiotropic cytokines is introduced along with its
founding member, TGF-ß1. Chapters 2 and 3 herein show that the ability of TGF-ß1 to
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inhibit cell cycle progression depends on its capacity to regulate mechanisms of CMG
formation and activation described above in this section.

The TGFß Superfamily

The transforming growth factor ß (TGFß) superfamily of cytokines evolved to
regulate a variety of cellular functions, including guiding developmental fate,
differentiation, proliferation, apoptosis, adhesion, creation of the extracellular matrix,
and skeletal homeostasis [169]. In addition, TGFß family members play roles in
controlling angiogenesis, as well as modulating the strength of immune responses
[170]. In fact, it is striking how many processes TGFß family members are involved in
and how critical they are for the morphogenesis and maintenance of multicellular
organisms. The complexity of TGFß function is compounded by the various contextual
determinants that control dynamic intracellular signaling through the Smad proteins and
other non-canonical pathways [171]. During tumorigenesis many, if not all, of the same
processes that TGFß family members control are deregulated to encourage
tumorigenesis. However, functions of TGFß can lend themselves to tumor prevention or
promotion. The complexity of TGFß signaling allows cancers to both disable tumor
suppressive mechanisms, while concurrently usurping pro-tumorigenic roles [172, 173].
Studies have shown that other genetic backgrounds may differentiate between these
conflicting effects for tumorigenesis [174].
A critical cell-autonomous role for TGFß in tumor suppression is the ability to
promote cytostasis via the inhibition of proliferation [173]. The founding member of the
31

TGFß family, TGF-ß1, is primarily involved in this anti-tumorigenic process, and various
types of cells are normally sensitive to TGF-ß1 growth arrest in G1 phase. However,
cancer cells of almost all forms exhibit a loss of sensitivity to TGF-ß1, highlighting this
defect as a key switch during tumorigenesis [173]. The ability of TGF-ß1 to induce
potent cell cycle arrest has been shown to involve the manipulation of the cell cycle
machinery and Rb pathway, however several observations involving TGF-ß1 inhibition
have left many unanswered questions regarding the identity of the critical underlying
molecular mechanisms that have persisted for many years [175]. In Chapters 2 and 3,
we have identified molecular answers to these remaining questions that indicate control
over the dynamics of the CMG helicase is critical endpoint for TGF-ß1 cell cycle arrest.

TGFß Members/Functions and Consequences in Cancer
In humans there are more than 35 different peptides that comprise the TGFß
superfamily. Among these, two major classes exist to distinguish various cellular roles.
First, the TGFß proper group consists of the activins, lefty, nodal, myostatin, and the
TGFß proteins. The second BMP branch consists of bone morphogenic proteins
(BMPs), anti-muellerian hormone (AMH), multiple growth and differentiation factors
(GDFs) [176]. Many of these factors are only expressed during development to control
stem cell differentiation, body polarity and left-right symmetry, as well as controlling the
generation of organs. These processes are controlled by nodals, activins, GDFs, BMPs,
and AMH primarily [173]. While the roles of some of these cytokines end during
development (e.g. AMH), others persist throughout the lifetime of an organism (e.g.
BMP2). Also in the adult, muscle development is regulated by myostatin, whereas the
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BMPs are necessary for the growth and repair of bone [177]. The expression of specific
TGFß family members is also highly variable between cell types. For instance, TGF-ß1
is evident in many cell types whereas myostatin is only expressed in select cells like
muscle [173].
In the first section of Chapter 1 herein, the multitude of cellular and
microenvironmental processes that are deregulated during tumorigenesis is discussed
[5]. The TGFß family plays a role in the normal maintenance of many of these same
processes to maintain homeostasis, and therefore, is a crucial target of deregulation for
cancer progression [170, 172]. One such overlapping process is control over cellular
proliferation. TGFß can both suppress the growth of cells to prevent cancer, but
depending on the cellular context (and the genes that are activated/repressed) can also
act to promote proliferation. The mechanisms that contribute to the Inhibition of cell
cycle progression by TGFß will be discussed in greater detail in the “TGF-ß1 Cell Cycle
Arrest” section below. While the growth of most epithelial and hematopoietic cells is
inhibited, other mesenchymal cells such as smooth muscle are normally stimulated to
grow by TGFß. This function is mediated by the induction of PDGF, which can stimulate
the growth of mesenchymal cells through an established autocrine loop [178].
Deregulated autocrine signaling is an established mechanism by which cancers lose
dependency on growth factor signaling to proliferate, and aberrant or enhanced
induction of PDGF by TGFß can promote these effects. For instance, TGFß signaling
stimulates the proliferation of glioma and osteosarcoma cells, both via the induction of
PDGF [179, 180].
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Another acquired characteristic of cancer, in which TGFß deregulation plays an
integral role, is the circumvention of programmed cell death mechanisms such as
apoptosis and autophagy [170]. TGFß can provide both pro-apoptotic and anti-apoptotic
functions, depending on the conditions, and these mechanisms are both lost and
harnessed in cancers to promote tumorigenesis. TGFß stimulates the activity of several
pro-apoptotic genes, such as death-associated protein kinase (DAPK) and BIM [181,
182]. Studies have shown that there are deficiencies in these pro-apoptotic mediators in
cancer that would dampen TGFß control over apoptosis. The destabilization of BIM, for
example, leads to the development of follicular lymphoma [183]. On the other hand,
TGFß-dependent anti-apoptotic functions are also deregulated in cancer. The
differentially expressed in chondrocytes 1, or DEC1, gene has anti-apoptotic function,
and TGFß can stimulate its action under certain conditions [184]. To circumvent the
control of these TGFß effects, DEC1 is commonly overexpressed in tumors, such as
breast carcinomas, and its degree of expression is a determinant for tumor grade [185,
186].
The production of new blood vessels via angiogenesis is a key process to
support development and wound healing, and cancer cells frequently take over this
program to facilitate tumor expansion [5]. TGFß has been shown to induce
angiogenesis by modulating the activity of angiogenic factors such as VEGF in epithelial
and fibroblastic cells [187]. Consistent with this pathway being important for cancer
development, increased expression of TGFß has been connected to an increase in
microvessels in tumors [188]. In other contexts, cancers may need to inhibit TGFß
function to promote angiogenesis. An example is thrombospondin 1 (TSP1), an
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angiogenic inhibitor that is induced by TGFß. In this case perturbation in TGFß signals
leads to accelerated angiogenesis and tumor growth [189].
Immune evasion is yet another determinant of cancer progression in which
TGFß plays both positive and negative roles [173]. TGFß is able to limit inflammatory
responses from the intestinal mucosa or T cells, and therefore the tumors that arise
from chronic inflammation. In addition, TGFß influences immune tolerance by inhibiting
differentiation of pro-inflammatory cells, such as NK cells, macrophages, and cytotoxic
T cells, or by promoting the recruitment of anti-inflammatory cells such as T regulatory
cells [173]. As such, tumors can arise by skewing the balance between tumorsuppressive benefits of TGFß in immunity and its normal immunosuppressive roles.
This imbalance drives the development of several cancers, including colon cancer,
glioma, and melanoma [173].
A large determinant of cancer mortality is the ability of a tumor to invade
surrounding tissues, leave the primary tumor, and colonize distant sites with metastasis
[5]. TGFß enables each of these metastatic processes when it is deregulated in cancer
[170]. Invasion of normal tissues by cancer cells involves the loss of cell-to-cell contact
and the adoption of more fibroblastic features, termed EMT. It has been shown that
TGFß can induce EMT in normal epithelial cells, which many tumor cells take
advantage of to promote their progression [190]. TGFß effectors such as SNAI1, SNAI2,
ZEB1, and ZEB2 can abolish adheren junctions by inhibiting E-cadherin, leading to
invasion [191]. Epigenetic silencing of the CDH1 (E-cadherin) gene itself is a
mechanism for TGFß-induced EMT, as hypermethylation of its promoter region occurs
following TGFß stimulation [192]. Additionally, TGFß can modulate the p53 pathway to
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influence EMT. TGFß induces MDM2 expression in mouse mammary epithelial cells,
which can inhibit p53-dependent anchorage [193].

Intracellular Signaling via Smad Proteins and Non-Canonical Pathways
Beyond cell type, the contextual determination of TGFß function in the aforementioned
processes is largely controlled by the specifics surrounding its transduction of signals
(Figure 1.6). The TGFß family of ligands signal through various receptors that converge
on intracellular effectors, which simultaneously stimulate or repress genes to govern
cellular responses [173]. The three main isoforms of the TGFß proper arm of the
superfamily are TGF-ß1, TGF-ß2, and TGF-ß3. They have key roles in many of the
processes that define TGFß function in general, and function as ligands that bind
extracellular receptors to transduce a multitude of various signals [172]. TGFß actually
exists in the cellular microenvironment as a latent molecule that is processed by matrix
metalloproteinases, integrins, or furins by proteolytic cleavage, and dimerizes to form
the active molecule [194, 195]. These active dimers of TGFß have high affinity for cell
surface receptors that facilitate intracellular signal transduction. Depending on the
specific ligand, TGFß molecules will signal through one of many type I and type II
receptors (TßRI and TßRII, respectively) with serine/threonine kinase activity [173].
Upon activation, TGFß ligands have high affinity for TßRII homodimers that have
formed at the cell surface independent of ligand [196].
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Figure 1.6: Canonical TGFß Signaling. TGFß ligand binding activates kinase
activity of hetero-tetrameric complexes of type I and type II receptors. Signals
are transduced by Intracellular phosphorylation of R-Smads and the formation of
hetero-trimeric complexes with Smad4 that are transported to the nucleus to
modulate TGFß target genes. Both R- Smads and Smad4 undergo
nucleocytoplasmic shuttling in the absence of ligand.

The major TßRI is the activin receptor-like kinase 5 (ALK5), or TGFßR1, which
forms heteroligomeric complexes with and is activated by ligand-bound TßRII proteins
[172]. These interactions involve both extracellular and intracellular domains, and result
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in transphosphorylation of both TßRI and TßRII, as well as the transduction of TGFß
signals [197]. The overexpression of TGFß is a common occurrence in a variety of
cancers in late stages of tumorigenesis, and correlates with tumor aggressiveness,
metastasis, angiogenesis, and poor prognoses [172]. TGFß receptors are also a point
of alteration in cancers, as TGFßR1 and TGFßR2 are also lost frequently, either at the
allelic level or by transcriptional repression/DNA methylation [172, 177].
The activation of oligomeric receptors by TGFß leads to the downstream
activation of the effectors of TGFß signaling, transcriptional coregulators called Smads
(Figure 1.6) [177]. The Smad proteins adopted their name by a combination of the SMA
and MAD genes, which transduce signals of TGFß homologs in C. elegans and
Drosophila respectively [177]. Smads structure is made up of two main globular
domains, termed the Mad-homology domains 1 and 2 (MH1 and MH2). The aminoterminal MH1 domain has a hairpin structure that facilitates DNA binding, whereas the
MH2 domain enables versatile interactions with activated TGFß receptors, cytoplasmic
adaptor proteins (e.g. SARA), as well as various co-activators and co-repressors of
transcription [171]. The MH1 and MH2 domains are connected by an unstructured linker
domain, that can be edited by factors like MAPK or ubiquitin ligases to modulate TGFß
signaling and mediate crosstalk with other growth pathways [170]. Receptor regulated
smads (R-Smads) interact with and are phosphorylated by receptor complexes. The
activated TSRII-ALK5 complex primarily phosphorylates R-Smads Smad2 and Smad3,
while other receptors like ALK1 activate Smad1, Smad 5, and Smad 8. However, upon
phosphorylation all R-Smads seem to interact with the Co-Smad, Smad4, which was
identified as a candidate tumor suppressor termed deleted in pancreatic cancer 4
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(DPC4) [170, 198]. Smad4 is commonly perturbed in cancer either by mutation or allelic
LOH as would be true of a classic tumor suppressor gene, however the presence of
only one functional Smad4 allele has been shown to be ‘haploinsufficient’ for the
prevention of neoplasia [4, 26, 172, 199-201]. R-Smads and Smad4 are not static
proteins that await ligand binding to function. In the absence of signal and activation,
Smads are dynamically shuttling between the cytoplasm and the nucleus via
nucleoporin interactions. This process acts like a sensing mechanism, maintaining the
Smads poised and ready to transduce TGFß signals [202, 203]. However, trimers
containing two R-Smads and one Smad4 molecule are believed to be the functional
complex, which require nuclear import and export factors to mediate TGFß signals
[177]. In Chapter 2, however, we present evidence that suggests R-Smads and Smad4
stability are critical for TGF-ß1 cell cycle arrest in late G1 involving a non-transcriptional
role. Negative regulation of TGFß signaling in response to antagonistic signals is carried
out by Smad6 and Smad7, which are termed the inhibitory Smads (I-Smads). Smad6 is
responsible for inhibiting Smad1 interactions through competitive binding, and functions
mainly in the BMP pathways [173]. Alternatively, Smad7 is mainly involved in disrupting
TGF-ß1 signaling through Smad2/3 by recruiting the Smurf E3 ubiquitin ligase to
receptors and promoting their degradation [204]. Deregulation of Smad7 is also
observed in cancers, such as endometrial carcinomas and thyroid follicular tumors
[173]. While Smads are primarily responsible for effecting TGFß signals, non-canonical
pathways also exist that complement the Smad pathways [171]. For example, TGFß is
known to signal through the RHOA GTPases, and the MAPK and PI3K networks also
converge on the Smad pathway to modulate signaling [171, 205].
39

TGF-ß1 Cell Cycle Arrest
As was mentioned in previous sections, TGF-ß1 is a vital regulator of cellular
proliferation, and these functions are key for maintaining homeostasis. Integral to this
process is the ability of TGF-ß1 to induce potent cell cycle arrest during G1 phase [175]
Indeed, almost all tumors display insensitivity to TGF-ß1 growth arrest, which can occur
via several pathway aberrations mentioned previously. In addition, the pathways that
mediate TGF-ß1 cell cycle arrest are commonly altered in cancers, if not all (e.g. CDKRb) [4]. Knowledge of the importance these same pathways for cancer has provided
new treatment opportunities [98]. While significant mechanisms that control TGF-ß1
arrest are known, other evidence including previous work from our group has shown
that additional unidentified mechanisms exist that are critical for TGF-ß1 control.
Therefore, elucidating the details of these unknown molecular mechanisms is critical for
our complete understanding of tumorigenesis (and how to prevent it). In the following
sections, canonical mechanisms for TGF-ß1 arrest are outlined, as well as these yet
unanswered questions.

CDK Regulation and Rb
There is an abundance of evidence that TGF-ß1 signals manipulate multiple
facets of the cell cycle machinery to elicit a potent and multifaceted growth arrest.
Cyclins necessary for G1 and G1-S progression are targets of TGF-ß1 [175]. However,
the proteins affected by TGF-ß1 stimulation can vary between cell types. In a human
keratinocyte (HaCaT) and mink lung epithelial cells (Mv1Lu), early G1 treatment with
TGF-ß1 blocks the induction of cyclin A and cyclin E mRNA by late G1 [206, 207].
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However, the subsequent loss of cyclin A and cyclin E protein does not occur in both of
these studies. However, in Mv1Lu cell lines where cyclin E protein was not blocked by
TGF-ß1, the association of cyclin E with CDK2 still did not occur by late G1, and
accordingly the cyclinE-CDK2 enzyme was not active [207, 208]. TGF-ß1 inhibition of
cellular proliferation has also been attributed to its ability to induce 4EBP1 protein, an
inhibitor of translation [209]. Knocking down 4EBP1 in pancreatic cancer or HaCaT cell
lines with shRNA or siRNA, as well as biallelic deletion in mouse embryonic fibroblasts
(MEFs) renders the respective cell lines insensitive to TGF-ß1 arrest [209]. Cell-type
specific cyclin A and E protein inhibition may also be explained by a variable
requirement for concomitant TGF-ß1-mediated inhibition of translation. In addition,
4EBP1 induction would affect the translation of many other cell cycle regulators that
may be mediators of TGF-ß1 growth arrest. In fact, CDK4 is also inhibited at the
translational level in Mv1Lu cells by TGF-ß1 treatment, and ectopic CDK4 expression in
these cells can perturb TGF-ß1 growth arrest [210].
The activity of CDK inhibitors (CDKi) is a more well-defined mechanism by which
TGF-ß1 modulates the activity of cell cycle mediators to arrest cells [88, 173]. In many
epithelial cells, TGF-ß1 induces the expression of p15Ink4b and increases its inhibitory
interaction with cyclinD-CDK4/6 complexes [211]. In addition, the p21Cip1 CDKi, which
inhibits cyclinE/A-CDK2 complexes, is also upregulated in response to TGF-ß1
stimulation. Both p15Ink4b and p21Cip1 are activated at the transcriptional level by
Smad3/4 complexes that contain FoxO transcription factors [212, 213]. Another CDKi
implicated in TGF-ß1 cell cycle arrest is the cyclinE-CDK2 inhibitor, p27Kip1. Protein
expression of p27Kip1 does not fluctuate throughout the cell cycle, as it is expressed in
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both asynchronous and quiescent cells [88]. Instead it has been demonstrated that
p27Kip1 is mobilized in response to TGF-ß1 stimulation. p27Kip1 is sequestered via
interactions with cyclinD-CDK4, but upon TGF-ß1 treatment, the CDKi is free to inhibit
cyclinE-CDK2 [173]. Much like cyclin and CDK responses to TGF-ß1, the activation of
specific CDKi seems to be cell type specific [214-216]. Regulation of CDK activity also
involves the protein phosphatase Cdc25A, which is necessary to activate CDKs. TGFß1 has also been shown to repress the expression of Cdc25A, which results in the
inactivation of CDKs [217].
Many of the cell cycle regulations discussed above converge on the Rb protein,
blocking its phosphorylation and retaining it in an antiproliferative state [37]. Therefore,
the idea emerged that hypophosphorylated Rb was the ultimate effector of TGF-ß1. In
fact, viral transforming proteins that bind and inhibit Rb function desensitize cells to
TGF-ß1 cell cycle arrest [218]. Additionally, TGF-ß1 treatment has been shown to
diminish Rb hyperphosphorylation [219]. For these reasons, TGF-ß1 growth arrest is
thought to critically require an intact Rb protein.

Suppression of c-Myc
The suppression of the oncogene c-myc also seems to be an important
molecular event for TGF-ß1 growth arrest [175]. C-Myc is critical for cellular proliferation
[220]. It has been demonstrated that at least one critical function of c-Myc is its
repression of p15Ink4b and p21Cip1 at their promoters via coordination with Miz1 [221,
222]. Additionally, c-Myc expression inhibits the mobilization of p27Kip1 to cyclinE-CDK2
complexes leading to its activation [223]. At the same time, studies have shown that c42

myc regulates the expression of G1 cyclins [175]. The TGF-ß1 pathway directly targets
the c-MYC promoter for repression via Smad3/4-C/EBPß complexes, which results in a
significant reduction in c-myc protein [224]. Loss of c-myc would result in abrogation of
all of these functions that promote proliferation via modulation of the cell cycle
machinery. Therefore, c-myc suppression is a critical mechanism by which TGF-ß1
inhibits cellular proliferation. Consistent with this idea, ectopic c-myc expression is able
to overcome TGF-ß1 cell cycle arrest [225]. The broad range of functions that c-myc is
involved in may provide future insight into events that TGF-ß1 must target to elicit
growth arrest [153].

Control of Replication Machinery
The majority of the studies described above were carried out by treating cells
with TGF-ß1 in early G1 and assessing the molecular effects that have occurred as a
result by late G1. Although these experiments had yielded a great deal of information
about mechanisms for TGF-ß1 growth arrest, none of these results conclusively explain
the ability of TGF-ß1 to inhibit cell cycle progression if stimulation does not occur until
late G1 [218, 226]. By this time CDKs have become active, c-myc has already acted,
and Rb is hyperphosphorylated. In addition late G1 coincides with TGF-ß1 growth arrest
that is independent of transcriptional control, which dictates the majority of these
mechanisms [227]. However, work from our group provided an explanation for this
phenomenon and provided entirely novel mechanism of TGF-ß1 regulation throughout
G1. Our studies show that TGF-ß1 inhibition in late G1 phase requires an intact
interaction between the amino terminus of Rb (RbN) and the Mcm7 subunit of the CMG
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helicase (discussed above in “DNA Replication”) [52]. Rb begins to interact with Mcm7
(and the helicase) in middle to late G1, and as cells move into S phase, the interaction
is no longer detected. Late G1 TGF-ß1 treatment prevents this disassociation of RbN
and Mcm7, and cell cycle progression is inhibited [52]. This provided physiologic
relevance to previous reports showing that the RbN-Mcm7 interaction was needed to
mediate RbN inhibition of DNA replication in Xenopus extracts [228]. Additional
regulation of the DNA replication machinery was observed in these studies. While early
G1 treatment also resulted in the suppression of c-Myc, inhibition of cyclinE-CDK2, and
a reduction in Rb phosphorylation, the accumulation of MCM protein was also blocked
[52]. The DNA replication machinery, and specifically the CMG helicase, is a critical
regulator of the G1-S transition, and modulating their function may prove to be the
causal mechanism underlying TGF-ß1 cell cycle arrest.

Questions Remaining for TGF-ß1 Cell Cycle Arrest
Our studies have revealed that regulation of the DNA replication machinery by
Rb is critical for late G1 TGF-ß1 growth arrest. However, a biochemical understanding
of how RbN blocked cell cycle progression via MCM interactions, as well as the
residues of RbN involved were not described. These are important questions, not only
for our understanding of TGF-ß1 growth arrest, but also for the elucidation of normal
tumor suppressive mechanisms of Rb that may be lost in cancer. Additionally, it is not
understood whether canonical Smad signaling is required for RbN-mediated late G1
inhibition by TGF-ß1. If so, it would be the first description of a non-transcriptional role
for Smads in TGF-ß1 cell cycle arrest.
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The downregulation of c-myc and control of Rb phosphorylation via CDK
regulation are thought to be critical mechanisms governing TGF-ß1 growth arrest.
However, differential effects on these pathways in various cell types raise questions as
to whether these are in fact the crucial molecular events that mediate TGF-ß1 inhibition.
Cells lacking CDKi such as p27Kip1, p21Cip1, p15Ink4b all remain sensitive to TGF-ß1 [217,
229, 230]. In other instances, TGF-ß1 arrest occurs in the absence of c-myc
suppression [231]. The requirement for Rb is also in question for TGF-ß1 inhibition.
Significantly, while cells lacking Rb (and the inhibitory RbN domain) are insensitive to
TGF-ß1 treatment in late G1, they can be inhibited if TGF-ß1 treatment occurs early in
G1 [52]. Other studies have shown that Rb may be dispensable for TGF-ß1 under
certain conditions [232]. This is surprising, as all TGF-ß1 growth arrest is believed to
require functional Rb. Therefore, it is pertinent to elucidate the mechanisms underlying
Rb-independent growth arrest. Whether common mediators of TGF-ß1 are at play, or
more novel mechanisms involving the suppression of MCM proteins govern TGF-ß1
arrest in the absence of Rb remains to be seen. Additionally, it will be intriguing to
discover whether Smad signaling is also involved. In the following chapters, we explore
these crucial questions that remain for Rb and TGF-ß1 growth arrest.
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CHAPTER TWO:
THE N TERMINUS OF THE RETINOBLASTOMA PROTEIN INHIBITS
DNA REPLICATION VIA A BIPARTITE MECHANISM DISRUPTED IN
PARTIALLY PENETRANT RETINOBLASTOMAS
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Abstract

TGF-ß1 cell cycle arrest in late G1 requires an intact interaction between the Nterminal domain of the Rb tumor suppressor protein (RbN) and minichromosome
maintenance subunit 7 (Mcm7). We show here that late-G1 inhibition by TGFß1 also
requires both Smad3 and Smad4 proteins, concurrent with a period in G1 where acute
transcriptional control is not a requirement for TGFß1 growth arrest. RbN contains inframe exon deletions in partially penetrant hereditary retinoblastomas and is known to
impair cell growth and tumorigenesis. However, how such RbN deletions contribute to
Rb tumor and growth suppressive functions is unknown. Here we establish that RbN
directly inhibits DNA replication initiation and elongation using a bipartite mechanism
involving N-terminal exons lost in cancer. Specifically, Rb Exon7 is necessary and
sufficient to target and inhibit the replicative CMG helicase, resulting in accumulation of
inactive CMGs on chromatin. An independent N-terminal loop domain, which forms a
Projection, specifically blocks DNA Polymerase-α and Ctf4 recruitment without affecting
DNA polymerases ε and δ, or the CMG helicase. Individual disruption of Exon7 or the
Projection in RbN or Rb, as occurs in inherited cancers, partially debilitates the ability of
Rb/RbN to inhibit DNA replication and block G1-to-S cell cycle transit. However, their
combined loss abolishes these functions of Rb. Thus, Rb growth suppressive functions
include its ability to block replicative complexes via bipartite, independent, and additive
N-terminal domains. The partial loss of replication, CMG, or Pol-α control provides a
potential molecular explanation for how N-terminal Rb loss-of-function deletions
contribute to the etiology of partially penetrant retinoblastomas.
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Introduction

Mutational inactivation or deletion of the retinoblastoma (Rb) tumor suppressor
gene occurs in multiple cancer types, including retinoblastoma, osteosarcoma, and
breast and small cell lung cancers, and deregulation or inactivation of regulatory
components of the Rb pathway is a hallmark of human cancers [233]. The Rb protein
functions to harness a variety of cellular processes important in tumorigenesis, including
regulation of the cell cycle, apoptosis, differentiation, stress responses and DNA
replication. The role of Rb in these processes derives to a large extent from interactions
of proteins with the C-terminus of Rb that contains a large pocket domain [233-237],
and most Rb loss-of-function mutations compromise pocket structure and/or function
and are highly penetrant alleles of inherited cancer in humans and mice.
Multiple observations indicate that the N-terminal domain of Rb (RbN, residues 1400) also plays an important role in growth suppression and tumorigenesis. Indeed,
nearly 20% of cancer-associated in-frame mutations in Rb are located in the N-terminal
region [238]. These lesions leave an intact C-terminal pocket and generate stable forms
of Rb that bind E2F transcription factors and localize to the nucleus in a fashion similar
to wildtype Rb [53, 238-241]. Several in-frame RbN exon deletions have been reported
in familial retinoblastomas, including individual losses of exons 4, 5, 7 or 9 [54, 242244]. In-frame deletions and mutations have also been found in Rb exons 6 and 8 in
prostate cancers and astrocytomas, respectively [245, 246]. Further, in contrast to
pocket mutations, N-terminal in-frame deletions in Rb generally display partial
penetrance for the development of retinoblastoma [54, 238, 239, 242-244]. For
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example, transgenic mice expressing Rb transgenes with N-terminal in-frame deletions
produce a partial penetrance phenotype for tumor development [53]. Finally, forced
expression of such Rb alleles in mice can impair embryonic and postnatal development,
and cannot rescue the embryonic lethality of Rb-/- mice [53]. Thus, the RbN domain
must direct unique functions of Rb that harness tumorigenesis.
Rb regulates G1 cell cycle transit through its interactions with E2F transcription
factors [233]. However, through unknown means, Rb also blocks the initiation and
progression of S-phase through inhibitory effects on DNA replication in an E2Findependent manner [44, 247, 248]. For example, primary mouse embryo fibroblasts
(MEF) exhibit an intra-S checkpoint and inhibit DNA synthesis in response to DNA
damage [249], yet Rb-/- MEFs fail to elicit this checkpoint response and continue to
replicate DNA [92, 250-252]. Indeed, following irradiation-induced DNA damage, Rb
localizes to DNA replication initiation sites and suppresses hyper-replication [92]. In
Drosophila, dRb protein binds with dE2F to the chorion ori and interacts with ORC to
suppress origin firing [253, 254]. In both scenarios it is unclear how Rb blocks DNA
synthesis at replication sites.
The ability of Rb to control DNA replication has been suggested to be directed by
its N-terminal domain. First, yeast 2-hybrid and biochemical studies have shown that
RbN directly binds to the C-terminus of Mcm7, a subunit of the replicative CMG (Cdc45,
MCM, GINS) helicase, and Rb-Mcm7 complexes are observable in vitro and in vivo [52,
255, 256]. Second, RbN can inhibit DNA replication in vitro when added to replicating
extracts from Xenopus oocytes [162, 255]. Inhibition is manifest at both initiation and
elongation steps and is associated with a reduction in RPA loading, suggesting the
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CMG helicase is one component of the replication apparatus inhibited by RbN [162].
Third, incubation with the C-terminal domain of Mcm7 (Mcm7-CT) blocks the ability of
RbN to suppress DNA replication [162]. Fourth, in mammalian cells a TGFβ1-to-Rb
circuit acutely blocks S-phase entry by inhibiting the assembled CMG helicase at G1/S,
and perturbation of the Rb-Mcm7 interaction abrogates this arrest [52]. Finally, Rb
protein lacking RbN is compromised for blocking entry into S-phase [257].
The mechanisms by which Rb suppresses DNA replication and helicase activity
are unknown. Here we report a bipartite mechanism by which Rb inhibits DNA
replication, where the exon 7 domain of RbN is required to inhibit CMG helicase activity
at initiation and elongation steps, while a notable Projection domain derived from part of
exons 5 and 6 [241] suppresses DNA Pol-α and Ctf4 recruitment to replisomes. Loss of
either of these domains impairs the ability of RbN to suppress DNA replication, while the
combined loss of both regions abolishes the ability of Rb to inhibit DNA replication and
to block progression into S-phase in vivo. Thus, the ability of Rb to directly harness DNA
replication via specific N-terminal regions mutated in cancers contributes to its tumor
suppressor functions.

Materials and Methods

Cell Culture, siRNA, Rb Mutant Plasmids, Synchronizations, and siRNA
Transfections
SaOS-2 cells were from ATCC and were cultured in DMEM containing 10% fetal
bovine serum (FBS, Hyclone). Balb/MK cells were cultured and transfected as
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described [52]. MK synchronization-siRNA transfections were carried out by EGF
deprivation for 3.5 days with transfection of 25nM final Invitrogen Smad 3 or Smad4
siRNA Smart Pools on day one without EGF, respectively. Upon stimulation with EGF,
late-G1 (9 hr) TGFß effectiveness was determined via BrdU incorporation at 15 hr,
followed by anti-BrdU immunofluorescence. For SaOS-2, transfections were performed
as previously described [44, 257]. Rb alleles were expressed in pCMV-based vectors
containing HA epitopes. A GFP-expressing plasmid was co-transfected in each sample.
48 hr after transfection SaOS-2 cells were analyzed by FACS for DNA content after
separating for GFP positive (transfected) and GFP-negative (non-transfected)
populations. SaOS-2 transfections were performed in duplicate and results averaged,
followed by normalization to empty vector transfections. For MK transfections, the
plasmid pCS2+XlRb [gift from Anna Philpott; [258]] was expressed for 24 hr.

Antibodies
All antibodies were rabbit polyclonals and raised against human homologues,
unless specified. Mouse monoclonal antibodies anti-GST, anti-His6, and anti-HA were
purchased from Covance. Monoclonal anti-BrdU conjugated to Alexa 488 was
purchased from Invitrogen. Monoclonals anti-Mcm7, anti-Rb (polyclonal antibody raised
against mouse Rb), and anti-Psf2, were purchased from Santa Cruz, anti-Smad4, antibeta-Actin, anti-Histone H3 were purchased from Abcam, and anti-Smad3 and antiMcm3 were purchased from Cell Signaling. Anti-Mcm5 was generated and
characterized as described [111]. Anti-Orc2 was a gift from Rolf Knippers (Konstanz
University, Germany). Anti-Ctf4 was a gift from Anindya Dutta (University of Virginia).
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Antibodies raised against Xenopus laevis proteins: anti-XMcm2, anti-XMcm4, antiXMcm6, and anti-XMcm7 and were gifts from Dr. Julian Blow (University of Dundee,
UK). Anti-XRPA32, anti-XCdc45, and anti-XMcm10 were gifts from Dr. Johannes Walter
(Harvard Medical School, MA), anti-XRPA70 was a gift from Dr. William Dunphy
(California Institute of Technology, CA), anti-XPol-alpha used for assessment of RbN
experiments was a gift from Dr. Karlene Cimprich (Stanford University, CA), and antiXPol-alpha, anti-XPol-delta, and anti-XPol-epsilon used for assessment of peptide
experiments were gifts from Dr. Shou Waga (Japan Women’s University, Japan).

Preparation of Extracts, in vitro DNA Replication, and Protein Purification
Xenopus laevis egg extracts were prepared from Ca2+-ionophore activated
mature eggs as described [259]. Cytosol and membrane fractions were snap-frozen and
kept at -800C until needed. Egg extracts reconstituted from frozen cytosol and
membrane fractions were incubated with 500 sperm nuclei/µl, in triplicate. Radio-labeled
nucleotides (dCTP-alpha32P) were added for 150 min at 220C to measure DNA
replication rates [260]. Isolated DNA/sperm chromatin from the samples was
precipitated on filters, and the levels of DNA replication were determined by scintillation
counting, with results averaged and errors as SEM. Peptides for human RbN exons
were synthesized at the Moffitt Cancer Center Proteomics Core facility. GST-RbN
(residues 1-400), GST-RbC (residues 399-928), GST-Rb, and all mutant derivatives (all
human species) were expressed in pGEX-4T. His6-Mcm7CT was expressed in pET28a.
All proteins were purified from Escherichia coli as described [52]. Protein amounts used
in each replication reaction are indicated in each figure.
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Chromatin Pull-Down Assays, in vitro Protein Binding Assays, and
Immunoblotting
Reconstituted Xenopus egg extracts were incubated with 2,500 sperm nuclei/µl
for studies with peptides (250 µM each) or with 1,250 sperm nuclei/µl for studies with
RbN mutant proteins (1.5 µM each). Following incubation for 80 min at 220C, extracts
were diluted in chromatin isolation buffer [261] containing 80 mM KCl (high salt) or 20
mM KCl (low salt) when assessing CMG chromatin association. For analysis of DNA
Pol-α and Ctf4 recruitment in the presence of RbN mutants or peptides, the same buffer
was used but with 40 mM KCl or 80 mM KCl, respectively. Analysis of RPA and GSTRbN chromatin association was performed using buffer with 80 mM KCl. To isolate
chromatin, diluted samples were layered over 1 M sucrose and subjected to
centrifugation for 15 min at 16,000 x g. In vitro GST-RbN/His6-Mcm7 protein binding
assays were performed as described [52]. Immunoblotting was performed using
enhanced chemiluminescence.

In vitro DNA Elongation Assays
Elongation assays were performed using a modification of a published protocol
[262], where a substitution of roscovitine for the p27Kip1 Cdk-inhibitor protein was used
to block initiation of DNA replication [263]. Briefly, fresh egg extracts containing sperm
nuclei (4,000/µl) were incubated for 30 min at 220C to allow the first round of DNA
replication initiation and elongation to begin. The samples were diluted in buffer
containing 250 mM KCl, 25 mM MgCl2, 25 mM EGTA, 2 nM β-mercaptoethanol, 2 µg/ml
aprotinin, 2 µg/ml leupeptin, and 50 mM Hepes-KOH, pH 7.6, and spun through a 1 M
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sucrose cushion. The pellet containing chromatin pre-initiated for DNA replication was
resuspended at 500 nuclei/µl in fresh egg extracts supplemented with 100 µM
roscovitine to inhibit further initiation of DNA replication in the second nuclei that formed.
DNA replication elongation in the second nuclei was assessed as described above, in
the presence of 37.5 µM peptides or 375 nM RbN proteins.

Results

Smad Signaling is Required for TGF-ß1 Cell Cycle Arrest in Late-G1
Experiments assessing TGF-ß1 cell cycle arrest in late-G1 phase have
established that Rb/RbN interactions with Mcm7 are critical for inhibition by TGF-ß1,
and these effects are mediated independent of transcription [52, 116]. Smad proteins
function as transcription factors to mediate TGF-ß1 functions, however their
requirement for late-G1 TGF-ß1 arrest was not explored in these studies. To test this,
MK cells were synchronized and were released into G1 phase following transfections
with Smad3 and Smad4 siRNA, respectively, and the ability of TGF-ß1 to block cell
cycle progression was assessed in S phase via BrdU incorporation (Figure 2.1A).
Transfection of Smad siRNAs during synchronization results in significant knockdown of
Smad3 or Smad4 by late-G1 time points (Figure 2.1B). We found that non-transfected
MK cells and those transfected with siRNA against luciferase were sensitive to TGF-ß1
in late-G1. However, MK cells transfected with Smad3 or Smad4 siRNA, respectively,
lose sensitivity to TGF-ß1 in late G1 (Figure 2.1C). Representative fields illustrating late
G1 TGF-ß1 ineffectiveness after Smad3 or Smad4 knockdown are shown in Figure
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2.1D. Thus, late G1 TGF-ß1 growth arrest involving Rb-Mcm7 interactions also critically
requires both intact R-Smad and Smad4 signaling.

Figure 2.1: Smad Signaling is Required for TGF-ß1 Cell Cycle Arrest in
Late-G1. (A) Diagram of MK synchronization-Smad siRNA transfection
experimental design. Following TGF-ß1 treatment in late G1 (9 hr), cells were
pulsed with 10mM BrdU at 15 hr. (B) Knockdown of Smad3 and Smad4 in late
G1 via synchronization-siRNA transfection (25nM final concentration of siRNA).
Actin serves as a loading control. (C) Late-G1 TGF-ß1 effectiveness following
Smad knockdown was determined with BrdU incorporation in S phase. Triplicate
fields were counted, and the results were averaged; errors, SEM. One-sided ttest calculations: one asterisk, p<0.05; two asterisks, p<0.01 (statistical labeling
for both Chapter 2 and Chapter 3). Percent maximal TGF-ß1 inhibition is
plotted, normalized to results for non-transfected cells. Maximal inhibition with
late G1 TGF-ß1 was ~75% for non-transfected plates (called 100%) (D)
Representative immunofluorescence BrdU fields for quantification in panel C.
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The RbN Domain Inhibits DNA Replication via Interactions with Mcm7
Yeast 2-hybrid analyses established that the RbN domain binds to the Cterminus of Mcm7 [255] and full-length Rb or RbN protein inhibits DNA replication in
Xenopus oocyte-derived in vitro replicating extracts [162, 255]. Xenopus oocytes and
early stage embryos do not contain endogenous Rb protein [2, 258], which we verified
here using ectopically-expressed Xenopus laevis Rb (Xl-Rb) in murine cells as a
comparison and antibody validation (Figure 2.2A). Thus, the effects of added Rb in
these extracts is not due to competition issues with endogenous Rb. Using this system
to assess effects of GST-RbN on DNA replication, we confirmed these findings and
showed that RbN inhibition of DNA replication is titratable (Figure 2.2B). Further, preincubation of GST-RbN with His6-Mcm7-CT prevents RbN from inhibiting replication,
and suppression of RbN inhibition by Mcm7-CT is also titratable (Figure 2.2C). The
effects of Mcm7 were due to interactions with RbN, as incubation of His6-Mcm7-CT
alone does not affect DNA replication in Xenopus extracts (Figure 2.2D). As Xenopus
extracts are transcriptionally inactive [264] RbN directly inhibits DNA replication
independent of transcription. These results are consistent with a stoichiometric
mechanism by which RbN inhibits DNA replication via interactions with the Mcm7
component of the CMG helicase.
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Figure 2.2: RbN Inhibits DNA Replication by Impairing CMG Helicase Activity
and DNA Polymerase-α Recruitment. (A) Mouse keratinocytes (MK) were
transfected (Tfx) with a plasmid expressing Xenopus laevis Rb (Xl-Rb). Total protein
lysates from non-transfected and ~10k transfected cells were compared to total
lysates from ~20k X.l. embryonic nuclei for Xl-Rb protein presence by
immunoblotting. Coomassie blue staining is used as a loading control. Note that XlRb migrates slightly faster than murine Rb [Mm-Rb; [2]]. Note also that the antibody
used recognizes Xl-Rb, but is not as efficient at recognizing Mm-Rb. (B-E) DNA
replication was measured in vitro using Xenopus oocyte extracts and sperm
chromatin (B) Bacterially purified human GST-RbN protein was titrated into reactions
prior to nuclear assembly and the start of DNA replication. Control had no RbN
protein added, and a boiled sample controlled for lack of replication. Assays were
performed in triplicate and averaged; errors, SEM. Two asterisks represent p<0.01
for significance calculations, with reference to control. (C) Replication assays were
performed with a fixed amount of GST-RbN protein pre-incubated with indicated
increasing amounts of bacterially-purified His6-Mcm7-CT protein. Assays were done
in triplicate and averaged; errors, SEM.
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Figure 2.2 (continued). (D) Bacterially purified human His6-Mcm7-CT protein was
titrated into replication assays prior to nuclear assembly and the start of DNA
replication. Control had no His6-Mcm7-CT added. Assays were performed in
triplicate and averaged; errors, SEM. (E) Sperm chromatin was used to initiate DNA
replication assays in oocyte extracts, with or without added GST-RbN. Chromatin
was isolated and analyzed by immunoblotting for association of RPA70, DNA Pol-α,
DNA Pol-δ, and DNA pol-ε.

RbN Inhibits CMG Helicase Activity and the Recruitment of DNA Polymerase-α
RPA is a single-stranded DNA binding protein and loading of RPA on chromatin
is used as a surrogate measurement for CMG helicase functionality [263]. As expected
[162], incubation with RbN reduced levels of RPA bound to Xenopus sperm chromatin
(Figure 2.2E). We reasoned that RbN might inhibit binding of other components that are
also needed for DNA replication. DNA polymerase-α is a priming polymerase [156], and
inclusion of RbN significantly reduced the association of DNA polymerase-α with
chromatin in Xenopus extracts (Figure 2.2E). RbN did not reduce the levels of DNA
polymerase-δ or –ε bound to chromatin (Figure 2.2E), but instead caused an increase in
the levels of both polymerases. Thus, chromatin-associated reduction of DNA
polymerase-α by RbN was specific. Collectively, these findings indicate that RbN
suppresses DNA replication by blocking CMG helicase activity and by impairing the
association of DNA polymerase-α with replisomes.

Mechanism of RbN-Directed Inhibition of DNA Replication
In-frame exon deletions in the N-terminus of Rb are associated with partially
penetrant inherited retinoblastoma [238], and such Rb alleles are also partially
penetrant in provoking tumor formation in transgenic mice [53]. Given the effects of the
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RbN domain, we hypothesized that Rb N-terminal mutants might be impaired in their
ability to inhibit DNA replication.
Examination of the crystal structure and 3D space-filling models of the RbN
domain [241] revealed two finger-like structures, F1 and F2 (Figure 2.3A). The F1 finger
has been called a 'Projection' domain [241], and is encoded by part of Rb exons 5&6,
whereas the F2 ‘bulge’ is encoded by Rb exon 7 (Figure 2.3A). The Rb exon 7 encoded
F2 domain is lost in familial inherited retinoblastomas [244], while Rb exons 5 and 6 are
lost or mutated in certain cancers [243, 245].
To test the roles of these domains in harnessing DNA replication, peptides were
generated representing Rb exon 4 (aa 128-167), exon 5 (aa 168-179), exon 7/F2 (aa
202-241), exon 9 (aa 287-313), and the Projection/F1 domain (aa 173-187; from end of
the α-helix in exon 5 to the beginning of the α-helix in Ex6). These peptides were then
tested to assess if they could directly inhibit in vitro DNA replication in the Xenopus cellfree system (Figure 2.3B). Exon 4 and exon 9 peptides, and exon 5 peptide, which
contains only part of the Projection/F1 domain, did not block DNA synthesis. In contrast,
the peptide representing the entire Projection/F1 domain did inhibit DNA replication in a
titratable manner, as did the exon 7/F2 peptide. Notably, when the F1 and F2 peptides
were combined in the reactions, the inhibition of DNA synthesis achieved was additive
and titratable (Figure 2.3B, far right). We conclude that the Projection/F1 and Ex7/F2
domains represent two functional regions of RbN that are capable of directly inhibiting
DNA replication. Further, the additive nature of these peptides in blocking DNA
replication support a model whereby F1 and F2 regulate DNA replication through
independent mechanisms.
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Figure 2.3: The F2 and F1 Domains of RbN Inhibit DNA Replication by
Suppressing CMG Helicase and DNA Pol-α, Respectively. A) Model of crystal
structure of RbN domain. Exons lost in retinoblastoma are in color. F1 and F2
finger domains are notated based on 3D modeling. See text for discussion. (B)
Peptides representing exons from RbN were analyzed for inhibitory capacity
relative to GST-RbN using in vitro Xenopus oocyte replication assays. Exon
peptides are matched to the simplified line diagram in panel A. Assays were
performed in triplicate with molarities indicated for each peptide or GST-RbN, and
results averaged; errors, SEM. Significance for each is with reference to control.
(C&D) Sperm chromatin was isolated after performing in vitro DNA replication
assays +/- RbN-derived peptides. Chromatin was analyzed by immunoblotting for
RPA70 to measure CMG activity (C), or for DNA polymerases to assess
chromatin recruitment (D).
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The RbN Exon7/F2 Domain Inhibits CMG Helicase Activity and the Projection/F1
Domain Inhibits Recruitment of DNA Polymerase-α
To test if the F2 or F1 peptides blocked CMG helicase activity or Pol-α
recruitment, Xenopus in vitro replication assays were performed with or without each of
these peptides, and sperm chromatin was isolated after an 80 minute incubation. The
loading of RPA and DNA Pol-α onto sperm chromatin was then assessed by
immunoblotting. Incubation with the F2 peptide selectively reduced RPA association,
indicating this domain inhibits CMG helicase activity (Figure 2.3C), whereas the F1
peptide impaired recruitment of DNA Pol-α (Figure 2.3D). Neither peptide affected the
association of the leading strand DNA polymerases δ and ε with chromatin (Figure
2.3D); thus, the inhibitory effect of the F1 peptide on DNA pol-α recruitment is specific.
Notably, the addition of both the F2 and F1 peptides reduced both RPA and DNA pol-α
recruitment (Figure 2.3C-D, far right). Thus, the F2 and F1 domains of RbN elicit
specific, independent, and additive inhibitory effects on the DNA replication machinery.

The RbN F2 Domain Triggers Accumulation of CMG Helicases Without Affecting
Assembly
To test if Rb-directed inhibition of CMG helicase activity was due to a failure of
the CMG helicase complex to assemble on chromatin, sperm chromatin was incubated
with Xenopus oocyte extracts in the presence and absence of F2 or other peptides
(Figure 2.4A&B), or RbN protein (Figure 2.4C). CMG complexes were then allowed to
assemble prior to the start of DNA replication, and chromatin was isolated using low61

stringency and high-stringency buffers. Immunoblot analyses demonstrated that none of
the peptides blocked the association of CMG components (Mcm2-7 and Mcm10) with
chromatin under low stringency conditions. Rather, incubation with F2 peptide
specifically caused an enrichment of these CMG components on chromatin (Figure
2.4A). This effect was even more apparent in high-stringency conditions, where CMG
components (Mcm2-7, Mcm10, Cdc45, Psf2) were tightly retained on chromatin when
incubated with F2 peptide (Figure 2.4B). Similarly, the addition of RbN protein to the
reactions caused an enrichment of CMG components on chromatin (Figure 2.4C). Note
also that RbN caused an enrichment of DNA polymerases δ and ε on chromatin (Figure
2.2E), although individual peptides from RbN were not able to recapitulate this effect
(Figure 2.3D). CMG components normally become progressively lost from chromatin
during active DNA replication [102], resulting in easier extraction. Given that F2 and
RbN block helicase function, the accumulation of CMGs results from an inability to
become activated and extracted, rather than a gain of additional CMG interactions.
Thus, RbN and F2 promote the accumulation of tightly-bound and inactive CMG
helicase complexes on chromatin.

Loss of the F1 and F2 Domains Blocks the Ability of RbN to Inhibit DNA
Replication
As the F2 and F1 peptides recapitulated the inhibition of DNA replication by RbN,
we reasoned that these domains would be necessary for suppressing DNA synthesis.
To test this, RbN proteins lacking exon 4, exon 5, exon 7 (F2), exon 9, or the
Projection/F1 domain (Figure 2.5A) were generated and tested for activity in in vitro
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Figure 2.4: The F2 Domain of RbN Causes Accumulation of Inactive CMG
Helicases on Chromatin. (A-C) Sperm chromatin was isolated after performing in
vitro DNA replication assays +/- RbN-derived peptides (A and B) or +/- GST-RbN
(C). Chromatin was extracted with low salt buffer (A) or high salt buffer (B and C).
Samples were analyzed by immunoblotting for indicated components of the CMG
helicase or actin, as a loading control. The analyses shown in panel A and B were
derived from samples in the experiments shown in Figure 2.3D and 2.3C,
respectively. The samples used in panel C are the same as those in Figure 2.2E.

DNA replication assays. Loss of exon 4, exon 5, or exon 9 did not appreciably affect the
ability of RbN to suppress DNA replication, although the loss of exon 4 or exon 5
somewhat diminished inhibitory capacity (Figure 2.5B). Deletion of F2 or F1 significantly
impaired RbN-directed inhibition of DNA replication, which was totally abolished in a
deletion mutant lacking both the F2 and F1 domains (Figure 2.5B, far right). Thus, the
F1 and F2 domains of RbN contribute independent and additive functions in
suppressing DNA replication.
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Figure 2.5: Deletion of the F1 and F2 Domains Abolishes RbN-Mediated
Suppression of DNA Replication, CMG Helicases, and DNA Pol-α. (A)
Schematic shows structures of in-frame deletion mutants of RbN that were tested.
(B) RbN deletion mutants were analyzed for inhibitory capacity relative to wild
type RbN using in vitro Xenopus oocyte replication assays. All proteins contained
GST tags and were purified from bacteria. Equal addition of RbN proteins (100
nM each) was verified by immunoblotting with anti-GST antibody (bottom).
Results are averages from triplicate samples. Errors, SEM. Significance for
mutant RbN data is calculated with reference to wt-RbN results. (C) Sperm
chromatin was isolated after performing in vitro DNA replication assays +/- wild
type GST-RbN or the indicated GST-RbN mutant derivatives. Samples were
analyzed by immunoblotting for chromatin association of RPA70, RPA32, and
DNA Pol-α. Anti-Orc2 immunoblotting was used as a loading control.
(D) Replication assays were performed in which RbN proteins were tested alone
or added in pairs to rescue partial replication inhibition of single RbN mutants.
Equal molar amounts of each protein (100 nM) were added to reactions. Results
are averages from triplicate samples. Errors, SEM. Significance is calculated
against control results, and between single RbN mutant results versus combined
assays containing the same mutant RbN protein.
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To assess if the F1 or F2 domains affected CMG activity or DNA Pol-α
recruitment, in vitro DNA replication assays were performed in the presence or absence
of RbN proteins containing in-frame deletions, chromatin was isolated, and RPA and
DNA Pol-α association was determined by immunoblotting (Figure 2.5C). Analysis of
Orc2 levels served as a loading control. Wild type RbN blocked DNA Pol-α recruitment
and the association of RPA, as measured via RPA32 and RPA70 association (Figure
2.5C, left side), indicating that the CMG helicase was inhibited. RbN proteins lacking
exon 4, exon 5, or exon 9 also blocked DNA Pol-α recruitment and CMG helicase
activity. Notably, RbN protein lacking the F2 domain blocked DNA Pol-α recruitment but
not the association of RPA, whereas RbN protein lacking the F1 domain impaired CMG
activity but not DNA Pol-α recruitment (Figure 2.5C). Finally, RbN missing both the F1
and F2 domains was completely deficient in blocking RPA and DNA Pol-α recruitment
(Figure 2.5C, far right), consistent with the dual deletion mutant being severely deficient
for blocking DNA replication. Thus, F2 and F1 domains of RbN block CMG helicase
activity and DNA Pol-α recruitment, respectively.
Given that the F1 and F2 domains provided independent and partial inhibitory
functions toward DNA replication, we asked if RbN proteins lacking F1 or F2 could
produce full inhibitory function over DNA replication when added together, or with RbN.
Whereas RbN lacking F1 or F2 again caused only partial suppression of DNA
replication, adding wildtype RbN alongside RbN-DF1 or RbN-DF2 resulted in inhibition
of replication similar to RbN alone (Figure 2.5D). Likewise, co-addition of RbN-DF1 and
RbN-DF2 resulted in effective suppression of replication. These results demonstrate
that each RbN mutant protein can provide in trans an independent and additive
65

inhibitory function, suggesting that multiple RbN molecules can access the replisome to
elicit additive inhibitory effects.

The F1 and F2 Domains of RbN Suppress Elongation of DNA Replication
RbN has also been reported to inhibit the elongation steps of DNA replication
[162]. To assess if Rb uses similar mechanisms to inhibit elongation steps, a Xenopus
in vitro replication assay was used that specifically measures elongation, which in
contrast to initiation, is Cdk-independent [263, 265, 266]. Briefly, sperm chromatin was
mixed with oocyte extracts, allowed to form nuclei, and to begin replicating. Chromatin
was then retrieved, which stops ongoing replication activity, and this pre-initiated
chromatin was transferred to a second oocyte extract containing the Cdk small molecule
inhibitor roscovitine. RbN deletion mutant proteins or peptides were then added to these
second extract/chromatin samples. The extracts then form a new nuclear envelope and
DNA replication resumes from established replisomes.
Consistent with elongation measurements using other approaches [162], RbN
efficiently suppresses the elongation of DNA replication (Figure 2.6A). Loss of exon 4,
exon 5, or exon 9 did not disrupt the ability of RbN to inhibit elongation. In contrast, loss
of the F2 or F1 domains partially impairs this function of RbN, and deletion of both F1
and F2 abolished the ability of RbN to inhibit elongation (Figure 2.6A). As was the case
for the initiation reactions (Figure 2.5D), co-addition of RbN-DF1 and RbN-DF2 resulted
in suppression of elongation similar to that achieved with wt-RbN alone (Figure 2.6B),
indicating that both mutant proteins provide additive inhibitory functions in trans.
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Figure 2.6: F1 and F2 Domains of RbN Suppress Elongation of DNA
Replication. (A) RbN deletion mutants and wild type RbN were analyzed for
their ability to inhibit elongation steps during DNA replication. Elongation was
measured in the presence of 100 µM roscovitine in a second nucleus that
formed around pre-initiated sperm chromatin isolated after DNA replication in
the first set of nuclei. RbN proteins were not present before or during DNA
replication in the first set of nuclei, and were added just prior to nuclear
envelope formation in the second set of nuclei. Roscovitine inhibited >80%
of DNA replication in the second set of nuclei that formed (data not shown),
with remainder being derived from elongation at established replisomes and
normalized to 100% (control, no protein added). Experiments were
performed in triplicate and averaged; errors, SEM. Percentages shown are
% control. One-sided t-test calculations for statistics are shown, comparing
mutant RbN results to wt-RbN. (B) Elongation assays were performed using
RbN alone or a combination of RbN mutants each missing F1 or F2, or with
no protein added (control). Equal molar amounts were used of each protein.
Results are averages of three experiments; errors, SEM. Significance was
p<0.0007 for both comparisons to control. (C) Elongation assays were
performed as in (A), but using RbN-derived peptides. Experiments were
performed in triplicate and averaged; errors, SEM. Percentages shown are
% no-peptide control. One-sided t-test calculations for statistics are shown,
comparing peptide results to control lacking peptide.
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Furthermore, while exon 4, exon 5, and exon 9 peptides have essentially no inhibitory
effect on elongation, the F1 and F2 peptides impaired elongation to at least a modest
extent (Figure 2.6C), and when added together were effective at blocking elongation
(Figure 2.6C, far right). Thus, the F1 and F2 domains of RbN are necessary and
sufficient for inhibiting both the initiation and elongation steps of DNA replication.

F1 and F2 Mediate Ctf4 Abrogation and Chromatin/Mcm7 Interactions,
Respectively, by RbN
To gain further insight into the mechanisms by which F1 and F2 mediate RbN
regulation of DNA replication, we next determined if loss of F1 or F2 disrupted the ability
of RbN to interact with chromatin. Wild type RbN or RbN lacking F1, F2, or both F1 and
F2, were incubated with extracts and sperm chromatin templates as for replication
assays, and after assembly steps the chromatin was recovered by centrifugation and
extracted with detergent buffer to assess RbN chromatin affinity by immunoblotting.
Loss of F2, but not F1, significantly reduces the ability of RbN to bind tightly to
chromatin (Figure 2.7A), and loss of F2 renders RbN deficient for direct interactions with
Mcm7 (Figure 2.7B). These results suggest that the inability of RbN-DF2 to inhibit the
helicases is derived, at least in part, from a reduced ability of RbN to interact efficiently
with helicases on chromatin.
We next assessed whether the F1 domain interfered with other aspects of
replisome assembly involved in DNA polymerase-α recruitment. Recruitment of DNA
polymerase-α involves its tethering to replisomes and CMG helicases by Ctf4/And1
[160, 267-269]. Sperm chromatin was incubated with extracts in the presence or
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absence of F1, F2, or exon 5 peptides, and replisomes were allowed to assemble
followed by isolation of chromatin and extraction with detergent buffer. The inclusion of
F1 peptide again specifically blocked the chromatin association of DNA polymerase-α,
but not DNA polymerase-ε, and also blocked the binding of Ctf4 (Figure 2.7C). Inclusion
of RbN also blocked the association of Ctf4 with chromatin, and specific loss of F1
rendered RbN unable to block Ctf4 association (Figure 2.7D). We conclude that the F1
domain of RbN interferes with the assembly of replisomes by abrogating the recruitment
of DNA polymerase-α and the tethering factor Ctf4.

The F1 and F2 Domains Contribute to Antiproliferative Functions of Rb, and RbC
Regulates RbN in a Phosphorylation-Dependent Manner
We next determined if full length Rb were dependent on the F1 and F2 domains
for suppressing DNA replication. In vitro DNA replication assays were performed in the
presence or absence of wild type Rb, or Rb lacking F1, F2, or both F1 and F2. Whereas
full length Rb was efficient at inhibiting DNA replication, Rb lacking F1 or F2 was only
partially capable of inhibiting DNA replication, and loss of both F1 and F2 rendered Rb
completely deficient in its inhibitory capacity (Figure 2.8A). Thus, in the context of full
length Rb, the F1 and F2 domains contribute functions necessary for inhibiting DNA
replication in vitro.
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Figure 2.7: F2 Mediates Chromatin and Mcm7 Binding by RbN, and F1
Blocks Ctf4 Recruitment. (A) Sperm chromatin was isolated after performing in
vitro DNA replication assays in the presence of wild type GST-RbN or the
indicated GST-RbN mutant derivatives. Samples were analyzed by anti-GST
immunoblotting for equal input of RbN proteins, and for chromatin association of
the GST-RbN proteins after isolation. Histone H3 probing was used as a
chromatin recovery control. (B) In vitro protein binding assays were performed
with purified GST-RbN proteins bound to glutathione beads in the presence of
bacterially-expressed His6-Mcm7. After incubation, beads were recovered and
samples analyzed by immunoblotting for bound Mcm7 protein with anti-His6
antibodies. (C) Sperm chromatin was isolated after performing in vitro DNA
replication assays +/- RbN-derived peptides. Chromatin was analyzed by
immunoblotting for the indicated proteins to assess chromatin recruitment. Actin
was used as a loading control. (D) Sperm chromatin was isolated after performing
in vitro DNA replication assays +/- wild type GST-RbN or the indicated GST-RbN
mutant derivatives. Samples were analyzed by immunoblotting for chromatin
association of Ctf4. Immunoblotting with anti-GST verified equal input of GSTRbN proteins to each sample. Histone H3 probing was used as a chromatin
recovery control.
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Figure 2.8: F1 and F2 Domains of Rb Contribute to G1 Cell Cycle Arrest. (A) In vitro
replication assays were performed using bacterially-purified full-length Rb that lacked F1, F2,
or both, and compared to wildtype Rb (5 nM used in each reaction). Experiments were
performed in triplicate and averaged; errors, SEM. (B) Replication assays were performed with
bacterially-purified RbC titrated into reactions. Assays done in triplicate; errors SEM.
Immunoblot with anti-GST verifies loading of GST-RbC protein.
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Figure 2.8 (continued). (C) The ability of Rb proteins containing deletions of F1, F2, or both
domains to block G1-S progression was measured using a SaOS-2 G1-arrest assay. Plasmids
expressing Rb proteins with 10 phospho-mimicking glutamates at C-terminal residues (M10E),
or wild type Rb, were co-transfected into asynchronous SaOS-2 cells with a GFP expression
vector. After 48 hr cells were collected and analyzed for cell cycle phases by FACS analysis.
DAPI staining was visualized after sorting populations into GFP-positive (transfected) and GFPnegative (non-transfected) cells. The increase in G1 (2N) cells for each Rb protein expressed is
plotted after averaging results from three independent experiments performed in duplicate;
errors, SEM. Samples were normalized to empty vector transfections, and are graphed as %
wild type Rb control, which produced ~30% increase in G1-arrest (called 100%). Similar
expression of HA-tagged Rb proteins was measured by immunoblotting with anti-HA, shown
below the graph. (D) In vitro replication assays were performed comparing the inhibitory effects
of bacterially-purified wt-Rb (full-length, non-phosphorylated) to purified Rb proteins with 10
glutamates on the C-terminus (M10E derivatives). Rb-M10E variants also lacked F1, F2, or
both, as indicated. Rb protein levels tested were 5 nM (left graph) or 10 nM (right graph) final
concentrations. Equal Rb protein testing is verified below each graph (anti-GST immunoblots).
Assays were done with 3-6 replicates and averaged; errors, SEM. P-values (all < 0.01) were
obtained using one-sided statistical testing. (E) Replication assays were performed comparing
the inhibitory effects of wt-Rb to Rb-M10E, Rb-M9E (same glutamate substitutions as M10E
except T373 is normal), and Rb-T373E (single glutamate at residue 373). Protein loading (5 nM
each) is shown using anti-GST immunoblotting. Assays done in triplicate and averaged; errors,
SEM. (F) Model proposed based on the findings of this study.

It was interesting that the inclusion of the C-terminal domain of Rb (RbC) did not
override the diminished inhibitory effects of loss of F1 and/or F2 in the context of the
full-length Rb protein, since it has been shown that RbC alone (containing the large
pocket) is capable of inhibiting mammalian cells during S-phase [247] and RbC in
isolation is tumor-suppressive in mouse and culture studies [233, 238]. To address this,
we determined the effects of RbC (residues 399-928) on in vitro DNA replication using
the oocyte extracts. Intriguingly, RbC in isolation is indeed capable of suppressing DNA
replication, although not as effectively as RbN (compare Figure 2.8B to Figure 2.2B).
The mechanism by which RbC achieves replication suppression remains unclear [247],
but may contribute to published observations for RbC-induced growth suppression.
Nonetheless, the results obtained above for the more physiologically relevant full length
Rb proteins indicates that even if RbC does contain an inhibitory function when in
isolation, in the context of Rb the RbC domain does not provide an inhibitory function
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toward DNA replication. But as will be seen below, RbC does provide a regulatory
function toward RbN.
The expression of wild type Rb triggers G1-arrest in Rb–null SaOS-2
osteosarcoma cells [44, 257]. Although hyperphosphorylation impairs the tumor
suppressor function of Rb and prevents it from interacting with E2F complexes [50],
forced expression of an Rb protein containing C-terminal phospho-mimetic glutamate
substitutions at ten serine or threonine sites (called Rb-M10E) continues, intriguingly, to
provoke at least some level of G1-arrest [257] despite this form of Rb being deficient for
E2F binding [50]. Notably, loss of the N-terminus abrogates the ability of Rb-M10E to
elicit this block to G1-S transit [257]. These results indicate that Rb-M10E remains at
least partially capable of inhibiting an unknown target(s) in late-G1, and the N-terminus
is required. Based on our findings herein, we reasoned that N-terminal domains
involved in CMG helicase and DNA Pol-α regulation might be required for this
proliferative arrest. SaOS-2 cells were transfected with wild type Rb, Rb-M10E, or with
Rb-M10E lacking the F1, F2, or F1 and F2 domains. Exogenous protein expression for
each Rb derivative was similar (Figure 2.8C, bottom). As expected for an Rb protein
mimicking hyperphosphorylated Rb, Rb-M10E activity was diminished relative to wild
type Rb in inducing G1 arrest (Figure 2.8C), and loss of F1 or F2 individually reduced
the ability of Rb-M10E to elicit G1 arrest. Notably, the combined loss of F1 and F2
abolished the ability of Rb-M10E to induce any level of G1 arrest (Figure 2.8C, far right).
These results indicate that the ability of Rb to effectively suppress G1-S transit requires
the presence of an intact N-terminal domain, and specifically requires the F1 and F2
domains.
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An important reason for using Rb-M10E in the above experiment was that
inclusion of the ten glutamates removed E2F targeting and suppression from the
interpretations [50], allowing a focus on the remaining inhibitory effects of Rb derived
from its N-terminus. Interestingly, although such Rb phosphorylation is generally
thought to result in an inactive form of Rb with respect to regulating cell cycle
progression, an interpretation of our results was that phosphorylated Rb was active at
suppressing cell cycle transit via negative effects on DNA replication. However, we
suspected that this was not the case, and that the ability of Rb to inhibit DNA replication
was likely compromised by phosphorylation. We reasoned that our ability to observe a
G1-arrest phenotype in the SaOS-2 cells by Rb-M10E was potentially a derivative of
overexpressing high levels of Rb-M10E, allowing any remaining G1-arrest effect derived
from F1/F2 to be seen under such protein-elevated experimental conditions despite a
suppressive set of phospho-mimics. In addition, it has been shown that phosphorylated
Rb is not effective at suppressing DNA replication in mammalian cells, and must be
dephosphorylated in order to efficiently elicit S-phase inhibition [92].
Based on the above concepts, we predicted that non-phosphorylated Rb was
likely the more effective suppressive form of Rb toward DNA replication, and that
phosphorylation (via glutamate mimics) would diminish this effect. However, we also
predicted that higher levels of Rb-M10E might overcome such suppressive
modifications of Rb and become inhibitory in direct biochemical analysis. To test this,
we used Xenopus replication assays to assess how bacterially-purified Rb-M10E
compared to non-phosphorylated Rb in their abilities to inhibit DNA replication. We
showed in Figure 7A that wildtype Rb (non-phosphorylated) was highly effective at
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inhibiting DNA replication when tested at 5 nM concentration. Compared at this 5 nM
concentration, wildtype Rb was again highly effective at suppressing DNA replication,
whereas Rb-M10E was not capable of such inhibition (Figure 2.8D, left side). At the
same 5 nM concentrations, Rb-M10E proteins lacking F1, F2, or F1 and F2 were
equally ineffective at suppressing DNA replication. However, similar testing of Rb-M10E
derivatives at twice the molarity (10 nM) demonstrated that under such elevated
biochemical conditions Rb-M10E now began to display inhibitory effects toward DNA
replication, albeit not as effectively as non-phosphorylated wildtype Rb (Figure 2.8D,
right side). Intriguingly, at 10 nM conditions, Rb-M10E lacking F1/F2 remained
ineffective at suppressing replication, while mutants lacking F1 or F2 displayed partial
effects. The latter results obtained at higher molarities are remarkably similar to those
found in our SaOS-2 experiments using Rb-M10E derivatives, indicating that the results
obtained in mammalian cell analysis and frog extract testing are consistent when the
expression/protein level of Rb-M10E derivatives is taken into consideration. We
conclude that phosphorylation of Rb on its C-terminus diminishes the ability of Rb to
function as an effective DNA replication inhibitor, and that even if such phosphorylationderived suppression of Rb is overcome at higher molarities, the ability of Rb to
negatively regulate DNA replication clearly remains dependent on F1 and F2 domains.
A corollary of these results is that Rb protein added to the extracts is unlikely to be
appreciably phosphorylated by embryonic kinases that are present during the analysis
of DNA replication because such Rb molecules would become ineffective.
A recent study of structural changes in Rb due to C-terminal phosphorylation
demonstrated that single phosphorylation of T373 via glutamate substitution caused a
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conformational change in Rb such that the N-terminal domain folded back onto RbC,
resulting in disruption of E2F interactions [50]. Since T373E is one of the ten sites
altered in Rb-M10E, we asked whether the T373E substitution itself contributed to the
loss of Rb suppression of DNA replication. Rb-M10E was compared to Rb-M9E (with
T373 wildtype) and to Rb(T373E) containing only the single change. Rb-M9E
suppressed Rb inhibitory effects similarly to Rb-M10E (Figure 2.8E), indicating that the
T373E change is not dominant in abrogating Rb function, and that one or more of the
remaining C-terminal phospho-mimicking changes in Rb-M9E causes loss of Rb
inhibitory effects. Interestingly, relative to wildtype Rb, the single change of T373 for
glutamate causes a small but statistically significant loss of inhibitory capacity by Rb
(Figure 2.8E). Altogether, these results indicate that, in the context of full length Rb,
phosphorylation of RbC contributes a negative regulatory role toward the function of
RbN in inhibiting DNA replication. Importantly, the change in Rb structure elicited by
T373E [50] can diminish some of the inhibitory capacity of Rb toward DNA replication,
but not all. The latter result identifies a single phosphorylation site change in Rb that
abolishes E2F interactions [50], but leaves intact some of the inhibitory effects of Rb
toward DNA replication.
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CHAPTER THREE:
RB-INDEPENDENT CELL CYCLE ARREST BY TGF-ß1 IS MEDIATED BY
INHIBITION OF CMG HELICASE ASSEMBLY VIA SUPPRESSION OF CDC6
PHOSPHORYLATION AND A CDT1-MCM RECRUITMENT STEP

Abstract

Although growth inhibition by TGFß1 is thought to depend on the antiproliferative
function of Rb, cells lacking Rb remain sensitive to TGFß1 arrest in early-G1.
Intriguingly, Rb-independent TGFß1 arrest also occurs in the absence of c-Myc
suppression and CyclinE-Cdk2 inhibition. We have identified the mechanism by which
TGFß1 achieves G1-arrest in the absence of these mediators. TGFß1 inhibits the
assembly of CMG replicative helicases by suppressing recruitment of MCM subunits to
chromatin. Accordingly, the entire MCM heterohexamer fails to load onto DNA. Cdc6
phosphorylation at its serine 54 residue is critical for Cdt1-MCM recruitment and
hexamer chromatin loading. We found that TGFß blocks phosphorylation at this site,
and thus MCM loading does not occur. Consistent with TGFß1 signals blocking Cdc6mediated Cdt1-MCM loading, overexpression of Cdt1 promotes S-phase entry in the
presence of TGFß1, circumventing the need for Cdc6 phosphorylation. Importantly,
Cdt1 requires an intact C-terminal MCM-binding domain in order to overcome TGFß177

induced cell cycle arrest. These results indicate that TGFß1 interferes with the Cdt1mediated MCM recruitment step involving Cdc6 serine-54 phosphorylation, leading to
inhibition of CMG assembly and S-phase entry despite the lack of Rb and presence of
normal c-Myc and CyclinE-Cdk2 activities. These findings also provide an explanation
for the oncogenic nature of Cdt1 that derives from its ability to abrogate TGFß1 arrest
by promoting CMG assembly.

Introduction

The ability of Transforming Growth Factor ß1 to inhibit cell proliferation is often
lost in cancers due to abrogation of the molecular events mediating TGFß1 control over
the cell cycle. TGFß1 cell cycle arrest occurs during G1 and is mediated by multiple
negative effects on the cell cycle machinery. Expression of c-myc is acutely
downregulated [270-272], which allows induction of the cyclin-dependent kinase
inhibitor (CKI) p15INK4B [211, 273]. This and other CKIs, including p21Cip1 and p27Kip1,
are utilized by TGFß1 to inhibit the activity of Cdk4-CyclinD and Cdk2-CyclinE kinases
[210, 274]. The suppression of these kinases prevents the hyperphosphorylation of Rb
[219], resulting in the maintenance of Rb in a hypophosphorylated and growth-inhibitory
form that inhibits progression into S-phase. An important feature of the aforementioned
canonical growth-inhibitory signaling pathway for TGFß1 is that the growth-suppressive
form of Rb is thought to play a pivotal role in the cell cycle arrest that occurs. However,
several studies suggest that Rb, c-Myc suppression, and kinase inhibition may be
dispensable for TGFß1-induced growth arrest. Growth inhibition by TGFß1 can occur in
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cells lacking p27Kip1, p15INK4B, or p21Cip1 [214, 217, 229, 230], and downregulation of cmyc is not always associated with TGFß1-induced arrest [231]. Perhaps most
significant, TGFß1 can block cell cycle progression in early-G1 in cells that are lacking
the Rb protein [52] or in Rb-/- fibroblasts under low plating conditions [232]. Such
studies suggest that other unknown mechanisms exist that mediate TGFß1 arrest and
are independent of c-Myc suppression, kinase inhibition, and Rb function.
Insight into these questions derives from a role for TGFß1 growth-inhibitory
signals in suppressing mini-chromosome maintenance (MCM) assembly and activation
[52]. The MCM complex is a heterohexamer comprised of Mcm2-7 subunits. The MCM
complex is recruited to chromatin as part of the pre-Replication Complex (preRC) that
regulates initiation of DNA replication from chromosomal origins [102]. MCMs are
recruited to preRCs by the combined functions of Cdc6 and Cdt1 [127, 275, 276], and at
the G1/S transition Cdc45 and GINS are recruited to the pre-bound MCM hexamers,
forming replicative CMG helicases [154, 165, 277]. Treatment of cells with TGFß1 in
early-G1 suppresses MCM protein expression and, accordingly, blocks MCM chromatin
recruitment [52]. This contributes to growth arrest alongside c-Myc suppression and
kinase inhibition. However, once MCMs are loaded in late-G1, TGFß1 can still arrest
cell cycle progression by inhibiting activation of assembled CMG helicases [52]. The
latter requires an interaction of Rb with the helicases in late-G1 that appears to inhibit
their function (likely via RbN F1 and F2 domains identified in Chapter 2) [52].
Cells lacking Rb remain sensitive to growth arrest by TGFß1, but only if treated
with the inhibitor specifically in the early-G1 interval, prior to MCM/CMG assembly [52].
Intriguingly, we show here that this Rb-independent TGFß1 arrest occurs in the
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absence of negative effects on c-Myc expression and CyclinE-Cdk2 kinase activity. In
addition, the absence of Rb renders TGFß1 incapable of suppressing MCM protein
expression. The mechanism mediating TGFß1 cell cycle arrest under these conditions
involves inhibition of CMG helicase assembly, derived specifically from suppression of
the MCM recruitment and loading steps. Recruitment of the entire MCM hexamer is
debilitated, and therefore the efficient loading of tightly bound MCM hexamers is
blocked. Studies have shown Cdc6 phosphorylation at serine 54 enables Cdt1dependent MCM loading [135, 146], and we show here that TGFß1 inhibits this event.
Accordingly, overexpression of Cdt1, but not an MCM-binding mutant of Cdt1,
circumvents the need for Cdc6 phosphorylation and overcomes TGFß1-induced growth
arrest. These results provide evidence for a novel mechanism utilized by TGFß1 to
abrogate G1 progression that involves inhibition of CMG function through suppression
of a Cdt1-MCM recruitment step mediated by Cdc6 serine 54 phosphorylation.

Materials and Methods

Cell Culture, Synchronization, and Transfections.
Mouse keratinocytes (Balb/MK) were maintained as described [225]. TGFß1
(R&D Systems) was used at 10 ng/ml. Synchronization was achieved by culturing cells
in medium lacking EGF for 3.5 days [52]. Transfections utilized Fugene6 (Roche) or
polyethylenimine [PEI; [278]]. shRNA was expressed using pSuperior-based vectors
(Oligo Engine). Luciferase and Rb target sequences for each MK clone were described
previously [52]. Note that MK/Rb-shRNA clones #5&13 target the same C-terminal
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region in Rb, while clone #4 targets an N-terminal sequence. MK synchronization-siRNA
transfections were carried out by EGF deprivation for 3.5 days with transfection of 25nM
final Invitrogen Smad 3 or Smad4 siRNA Smart Pools on day one without EGF,
respectively. Upon stimulation with EGF, early-G1 TGFß effectiveness was determined
via BrdU incorporation at 15 hr, followed by anti-BrdU immunofluorescence.

Antibodies
Antibodies are rabbit, unless specified. From Covance: mouse monoclonal
(mAb) anti-HA (1:1000), anti-Smad4 (1:750) and mAb anti-HA-FITC (1:1000);
Calbiochem: mAb anti-PCNA (1:10,000) and anti-Rb (1:500); from BD Biosciences:
mAb anti-Orc4 (1:1000;) and anti-Mcm2 (1:3000); from Cell Signaling: anti-Smad3
(1:200), anti-Cdc7 (7 µl/assay), anti-Mcm3 (1:1000); from Santa Cruz: mAb anti-Mcm4
(1:200), mAb anti-Mcm6 (1:500), mAb anti-Mcm7 (1:1000), mAb anti-Cdc6 S54-P
(1:500), anti-CycE (5 µg/ml), and anti-Cdt1 (1:200); from Invitrogen: anti-BrdU-Alexa594
(1:20); from Sigma: mAb anti-Actin (1:5000); anti-Mcm5 (1:3000; Rolf Knippers,
Konstanz, Germany); anti-Myc (1:500; Steve Hann, Vanderbilt University); chicken antiCdc45 (1:1000) was described previously [52]. Rabbit polyclonal anti-Geminin (1:5000)
was generated for this study by Covance, Inc. Anti-Geminin specifically recognizes p33
Geminin and p73 LacI-Geminin on immunoblots (data not shown).

BrdU and Immunofluorescence
Replicating DNA was labeled by pulsing for 30 min with 15 µM
bromodeoxyuridine. BrdU detection and other IF assays were performed using standard
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procedures as described [52, 279].

Chromatin Preparations, Immunoblotting, and Kinase Assays
Equal cell numbers were lysed and boiled in loading dye (for total lysates; TCE),
or were separated into detergent resistant (P3/chromatin-recruited) or detergent-soluble
fractions as described [52, 115, 116]. PreRC subunits present in the chromatin-recruited
fraction are sensitive to nuclease digestion using this approach [115]. Salt-resistant
(load) samples were further extracted in the same buffer used for chromatin/P3
recruitment assays, but containing 80 mM KCl. Alternatively, salt-resistant samples
were extracted in the same buffer containing 500 mM NaCl [127], with similar results
obtained in immunoblotting experiments as shown for KCl extractions (data not shown).
TCE and chromatin or load samples representing equivalent cell numbers were
analyzed by standard immunoblotting techniques. Histone H1 kinase assays were
performed as described [52, 279]. Cdc7 kinase assays against His6-Mcm2 substrate,
purified from bacteria using standard methods, were performed as described [52, 280].

Results

TGFß1 Blocks MCM Protein Expression in Wildtype MK Cells, but Not in Those
Lacking Rb
Mouse keratinocytes (Balb/MK) are a model system for studying the growth
inhibitory signaling pathways induced by TGFß1 [52, 225, 227, 272]. MK cells are
synchronized in a quiescent state by EGF deprivation and released into the cell cycle,
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with the immediate G1-phase lasting 12-14 hours (experimental design illustrated in
Figure 3.1A).

Figure 3.1: Early-G1 TGFß1 Cell Cycle Inhibition in Rb Lacking Cells Does
Not Affect MCM Expression. (A) Diagram showing basic experimental design
throughout report. (B) Immunoblot showing effective stable shRNA-mediated Rb
depletion in two independent MK(Rb-) clones. Rb expression in MK-Luc-shRNA
cells is the same as in wildtype MK cells. A third MK(Rb-) clone (#4) also displays
Rb depletion, and p107 expression is not affected in all three clones. (C&D) The
indicated MK cell types were EGF-synchronized and treated with TGFß1 in earlyG1. BrdU analysis was used to determine the number of cells that could enter Sphase. Example fields of TGFß-inhibited populations are shown in D, and results
graphed in C as means of triplicate counts of >200 cells/field, +/- 1 s.d. (E)
Immunoblot of TGFß1 effect on Mcm2 and Mcm5 protein expression in
synchronized wildtype MK and MK(Rb-) clone #5, respectively. This clone is used
in the remaining panels.
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MK cells lacking Rb protein expression [called MK(Rb-) cells] do not arrest when
exposed to TGFß1 in late-G1, but remain sensitive to TGFß1 if the inhibitor is added
to such cells in early-G1 [52]. This was unexpected, since Rb has long been thought to
play a pivotal role in the events underlying TGFß1-induced cell cycle arrest [218, 219,
281]. We verified here that Rb protein is indeed absent by stable shRNA constructs
(Figure 3.1B), and that Rb is dispensable for cell cycle arrest following exposure to
TGFß1 in early-G1 (Figure 3.1C). The effective suppression of Rb protein by stable
shRNA constructs was confirmed in the three independent clones we generated.
TGFß1 treatment in early-G1 efficiently inhibited all three MK(Rb-) clones from entering
S-phase in a manner nearly identical to that achieved in wildtype cells or MK cells
transduced with shRNA against Luciferase (Figure 3.1C) (i.e. BrdU incorporation is
inhibited by early G1 TGFß1, represented by one clone in Figure 3.1D).
We showed previously that Mcm2 and Mcm7 protein expression during G1 are
blocked by TGFß1 treatment in early-G1 [52]. We asked whether this is also be
occurring in cells lacking Rb. As before, in wildtype cells, protein expression of Mcm2 is
blocked by early-G1 TGFß1, and we show here that Mcm5 is also suppressed in a
similar fashion (Figure 3.1E, top). In stark contrast, Mcm2 and Mcm5 protein is not
inhibited by early-G1 TGFß1 in MK(Rb-) cells (Figure 3.1E, bottom). Therefore, in
contrast with wildtype cells, MCM heterohexamer protein stability is unaffected by
TGFß1 in Rb-lacking cells.
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TGFß1 Blocks Cell Cycle Progression in the Absence of Rb, c-Myc, CyclinE-Cdk2
and Cdc7-Dbf4 Regulation in a Smad-Dependent Manner
Major contributors to cell cycle arrest mechanisms by TGFß1 include
suppression of c-Myc expression and inhibition of the activation of CyclinE-Cdk2 kinase
activity, both effects observable in wildtype MK cells treated with TGFß1 in early-G1
(Figure 3.2A, top & Figure 3.2B, top, respectively)[52]. Intriguingly, TGFß1 treatment of
MK(Rb-) cells in early-G1 does not inhibit c-Myc protein expression even though cell
cycle progression is inhibited (Figure 3.2A, bottom). This is consistent with previous
studies that have shown c-Myc mRNA and protein suppression by TGFß1 to be linked
to the presence of functional Rb protein [218]. Exposure of MK(Rb-) cells to TGFß1 in
early-G1 also fails to inhibit the activation of CyclinE-Cdk2 kinase (Figure 3.2B, bottom).
One explanation for this derives from the continued presence of c-Myc, which prevents
the induction of p15INK4B that promotes p27KIP1 inhibition of CyclinE-Cdk2 by TGFß1
[273, 282]. In addition, the presence of c-Myc promotes expression of Cyclin E and
Cdc25A, which activate Cdk2 kinase activity [217, 283-286]. The Cdc7-Dbf4 kinase is
involved in the recruitment of Mcm2 to preRCs [280], and is modestly inhibited by earlyG1 TGFß1 treatment in wildtype cells (Figure 3.2C, top). However, this inhibition does
not occur in MK(Rb-) cells under the same conditions (Figure 3.2C, bottom).
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Figure 3.2: TGFß1 Arrest is Not Mediated by Common Mechanisms in
Cells Lacking Rb, but Does Require Smad Signaling.
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Figure 3.2 (continued). (A) Immunoblot of TGFß1 effect on c-Myc protein
expression in synchronized wildtype MK or MK(Rb-) cells. (B) Effect of TGFß1 on
CyclinE-Cdk2 histone H1 kinase activity in synchronized wildtype MK (top) or
MK(Rb-) (bottom) cells using anti-CyclinE in the immunoprecipitation step.
Controls in MK(Rb-) cell cyclinE-Cdk2 kinase assay (bottom) are from same film
and exposure as the experimental samples. (C) TGFß1 effects on the kinase
activity of Cdc7-Dbf4 in synchronized wildtype MK and MK(Rb-) cells. Anti-Cdc7
immunoprecipitations were performed at times indicated, followed by in vitro
kinase assays using purified His6-HsMcm2 as a substrate. (D) Schematic
describing synchronization-transfection approach with Smad siRNA. (E)
Immunoblot of Smad3 and Smad4 expression following synchronization-Smad
siRNA transfection, respectively, in MK(Rb-) cells. Actin serves as a loading
control. (F) Graph of TGFß1 effectiveness in non-transfected synchronized
MK(Rb-) cells, or those transfected with Smad 3 or Smad4 siRNA, respectively.
Results graphed as means of triplicate counts of >200 cells/field, and normalized
to maximal inhibition in untransfected cells. (G) Example fields of TGFß1
effectiveness in Smad siRNA transfected cells.

Smad proteins are responsible for canonical signal transduction of TGFß1
messages [177]. We next asked if TGFß1 cell cycle arrest without these common
mediators is a Smad-dependent process. To address this question, MK(Rb-) cells were
synchronized, and transfected with siRNA against Smad3, Smad4, or Luciferase,
respectively (see experimental design, Figure 3.2D). Smad3 and Smad4 expression is
unaffected in cells released into G1 following Luciferase siRNA transfection throughout
G1 phase (Figure 3.2E), but Smad3 or Smad4 siRNA synchronization-transfection
blocks their protein expression, respectively (Figure 3.2E). In addition, siRNAs are
specific, as one Smad siRNA construct does not affect the expression of the other
(Figure 3.2E). MK(Rb-) cells and those transfected in this way with Luciferase siRNA
remain sensitive to TGFß1 in early-G1, however suppression of Smad3 or Smad4
abolishes TGFß1 cell cycle arrest in these cells, as measured by BrdU incorporation at
an S phase time point (Figure 3.2F). Representative BrdU immunofluorescence from
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the experiments in Figure 3.2F are shown (Figure 3.2G). Thus, in the absence of Rb,
TGFß1 fails to inhibit c-Myc, CyclinE-Cdk2, and Cdc7-Dbf4, but maintains the ability to
efficiently growth-arrest the cells after early-G1 exposure via R-Smad/Smad4 pathways.

TGFß1 Suppresses MCM Chromatin Recruitment and Loading via Inhibition of
Cdc6 Serine 54 in MK(Rb-) Cells
TGFß1 treatment in early-G1 does not alter the protein expression or chromatin
association of Cdc6 or Cdt1 in wildtype MK cells [52]. We show here that the same is
true in MK(Rb-) cells (Figure 3.3A, left and middle, respectively), and again that
expression of the entire heterohexamer is maintained (Figure 3.3A, left) . Although Cdt1
is known to be at least partially degraded during S-phase in human cells [287-289], we
do not observe such changes in murine cells (data not shown), nor in CHO cells [130].
Since human HaCaT keratinocytes analyzed with this anti-Cdt1 antibody demonstrate
that HsCdt1 protein is indeed diminished during S-phase (data not shown), it appears
that rodent cells may differ from human cells in Cdt1 dynamics. Therefore, MCMs
protein along with expression of proteins involved in recruiting MCM hexamers to
chromatin are unaffected by TGFß1 in MK(Rb-) cells.
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Figure 3.3: TGFß1 Inhibition of MCM Loading and Cdc6 Serine 54
Phosphorylation in Rb Lacking Cells. (A) Immunoblot analyses showing
TGFß1 effects on total protein expression and chromatin-recruited complement of
indicated proteins in synchronized MK(Rb-) cells. Samples were further extracted
with high-salt buffer to assess protein loading onto DNA. (B) Immunoblot showing
TGFß1 effects on total protein expression and chromatin-recruited Geminin in
synchronized wildtype MK cells, and chromatin-recruited Geminin in synchronized
MK(Rb-) cells. (C) Immunoblot analysis of TGFß1 effects on Cdc6 serine 54
phosphorylation in synchronized MK(Rb-) cells. A larger, nonspecific band serves
as a loading control.

We reasoned instead that this Rb-independent TGFß1 arrest might be derived
from inhibition of some aspect of the CMG helicase assembly process involving these
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proteins. The effects of TGFß1 on MCM chromatin recruitment and loading onto DNA
were assessed. TGFß1 treatment in early-G1 indeed suppresses the recruitment of the
entire MCM hexamer (Figure 3.3A, middle). We hypothesized that this altered
recruitment would not facilitate the tight loading of MCMs onto DNA. MCM loading is
measured by further extractions of chromatin-recruited MCMs with a higher salt buffer,
leaving only tightly-bound MCM subunits on DNA [127]. MK(Rb-) cells were collected in
late-G1 after an early-G1 TGFß1 treatment and compared to untreated cells. As
predicted, the entire MCM heterohexamer was efficiently blocked from becoming loaded
onto DNA in the presence of TGFß1 (Figure 3.3A, right). Intriguingly, the recruitment as
well as the loading of Cdc6 and Cdt1 is not blocked by TGFß1 (Figure 3.3A, middle and
right). Cdt1 and Cdc6 remain resistant to high salt extraction even in the presence of
TGFß1 (Figure 3.3A, right). We conclude that TGFß1 growth arrest in MK(Rb-) cells is
not associated with a failure of necessary MCM loading proteins (Cdc6 or Cdt1) to be
made or localized chromatin.
The effect of TGFß1 on Geminin dynamics was also examined. TGFß1 treatment
did not prevent the normal accumulation of Geminin on chromatin that occurs during
late-G1 and S phase in either wildtype MK or MK(Rb-) cells (Figure 3.3B, top and
bottom, respectively). Given that this increase of Geminin on chromatin is normally
involved in preventing re-loading of MCMs [148, 290, 291], the ability of TGFß1 to allow
Geminin to accumulate on chromatin in arrested cells may serve to sustain the inhibitory
effect of TGFß1 on MCM recruitment and loading, and Rb expression does not affect
this mechanism.
Phosphorylation of the amino terminus of Cdc6, including at serine 54, prevents
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its degradation and is required for MCM loading and DNA replication in vitro [135, 144,
146, 147]. It has also been demonstrated that perturbation of Cdc6 function stabilizes
Cdt1 at origins, but MCM loading remains blocked [124], which is consistent our results
showing TGFß1 blocking MCM (but not Cdt1) loading on to chromatin (Figure 3.3A,
right). In addition, TGFß1 exposure in early-G1 blocks Cdc6 phosphorylation in wildtype
MK cells [52]. We asked whether Cdc6 N-terminal phosphorylation is also affected by
early-G1 TGFß1 in MK(Rb-) cells. While total Cdc6 protein was unaffected by TGFß1
(Figure 3.3A, left), using an antibody that specifically recognizes Cdc6 phosphoserine54, we show that TGFß1 potently blocks Cdc6 phosphorylation at this site (Figure
3.3C). Therefore, we conclude that TGFß1 blocks MCM recruitment and loading by
inhibiting Cdc6 serine 54 phosphorylation.

Cdt1 Overexpression Abrogates TGFß1 Arrest in Rb Lacking Cells, and the MCM
interaction Domain of Cdt1 is Required
In the absence of Rb, TGFß1 no longer inhibits many of the mechanisms
regulating cell cycle progression and MCM assembly. CyclinE-Cdk2 and Cdc7-Dbf4
kinases are active, Myc is present, and Mcm2-7 proteins are expressed. Despite this,
TGFß1 cell cycle arrest occurs coincident with an absence of Cdc6 phosphorylation at
its serine 54 residue. Cdc6 N-terminal phosphorylation, including on serine 54, is crucial
for Cdc6-mediated pre-RC assembly [144, 146], and the actions of Cdc6 are known to
precede Cdt1-mediated MCM recruitment to chromatin [124, 135, 292]. This suggested
that some aspect of the MCM recruitment step involving Cdc6 was being abrogated by
TGFß1, upstream of Cdt1-MCM recruitment. We hypothesized that Cdt1
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overexpression in MK(Rb-) cells would circumvent the need for phospho-Cdc6 to load
MCMs, and would overcome TGFß1 cell cycle arrest.
An experiment was performed in which synchronized MK(Rb-) cells were transfected
during the EGF deprivation period with a vector expressing HA-Cdt1 (outlined in Figure
3.4A). A diagram illustrating full length Cdt1 is shown in Figure 3.4B. Cells were
released into the cell cycle, and immunoblotting showed that HA-Cdt1 became
expressed during G1 (Figure 3.4C, left lane). BrdU incorporation verified that cells
entered S-phase at ~12 hr (data not shown). Cells expressing HA-Cdt1 were BrdUnegative in early-G1, indicating that HA-Cdt1 expression does not cause premature Sphase entry (data not shown). Exposure to TGFß1 in early-G1 prevents non-transfected
MK(Rb-) cells from entering S-phase, but those expressing HA-Cdt1 in the presence of
TGFß1 fail to arrest in G1 and enter S-phase (Figure 3.4D, top row, and Figure 3.4E).
Overexpression of an unrelated splicing factor, HA-Psf1 (no relation to GINS subunit),
does not override TGFß1 cell cycle arrest (Figure 3.4D, bottom row). A graph
quantifying these results is shown in Figure 3.4F. Nearly identical results were obtained
with an independent MK(Rb-) clonal population (clone #4; data not shown). . In addition,
TGFß1 growth arrest of wildtype MK cells cannot be abrogated by HA-Cdt1
overexpression (Figure 3.4G), likely due to the presence Rb that blocks CMG activation
in late-G1 [52]. We conclude that elevated Cdt1 expression can specifically override
TGFß1-induced cell cycle arrest of MK(Rb-), coincident with a block of serine 54
phosphorylation. These data suggest that the Cdt1-MCM recruitment step is being
targeted by TGFß1 inhibitory signals via inhibition of Cdc6 phosphorylation, and ectopic
Cdt1 expression can override this suppressive mechanism.
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Figure 3.4: Cdt1 Containing its MCM-Interaction Domain Abrogates TGFß1
Cell Cycle Arrest in MK(Rb-) Cells.
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Figure 3.4 (continued). (A) Experimental design (Tfx, transfection). MK(Rb-) clone
#5 was used in panels B-H. (B) Diagram of HA-tagged wildtype Cdt1 and
truncation mutants tested. (C) Immunoblot using anti-HA to verify similar
expression of each HA-Cdt1 truncation mutant relative to wildtype HA-Cdt1 (full
length), in G1 from synchronized MK(Rb-) cells. “X” indicates a blank lane. (D)
BrdU was pulsed 15 hrs after release in HA-Cdt1- or HA-Psf1 transfected cells,
and IF was performed using anti-BrdU-Alexa594 and anti-HA-FITC. DAPI
staining, nuclei. Arrows, select HA-positive cells as references. (E) Larger field for
HA-Cdt1-transfected cells. The inset box I the area shown in panel D. (F)
Quantitation for MK(Rb-) cells expressing indicated proteins vs. non-transfected
cells; means of triplicate counts of ~150 cells/field, +/- 1 s.d. (G) Wildtype MK cells
transfected with HA-Cdt1 and analyzed as in panel D. (H) The ability of HA-Cdt1
truncation mutants to override TGFß1 G1-arrest in MK(Rb-) cells, versus wildtype
HA-Cdt1. Experiments were performed as in Figure 3.4D. Results are shown for
both TGFß1 treated cells (left) and untreated (right) cells.

Our results support a model whereby TGFß1 inhibitory signals target the Cdt1MCM recruitment step, with elevated Cdt1 S-phase entry in the presence of the growth
inhibitor. Accordingly, loss of the MCM-binding domain [128, 129] from Cdt1 should
disrupt the ability of Cdt1 to override TGFß1 cell cycle arrest. To test this, similar
experiments were carried out using two different Cdt1 truncation mutants were
generated (Figure 3.4B) and expressed in synchronized MK(Rb-) cells in G1 (Figure
3.4C, second and last lanes). One Cdt1 deletion mutant lacked the C-terminal Mcm6interacting domain [Cdt1(1-435)], while one lacked the N-terminal Cdt1 stability domain
[Cdt1(73-546)]. As predicted, overexpression of the Cdt1 mutant lacking the C-terminal
MCM-interacting region was unable to overcome TGFß1 arrest in MK(Rb-) cells (Figure
3.4H, left). The N-terminus of Cdt1 binds factors that promote Cdt1 degradation, and
ectopic expression of this domain competes out the function of these factors and allows
endogenous Cdt1 to stimulate re-replication [129]. It was possible that overexpression
of Cdt1 was similarly competing out the function of proteins involved in Cdt1 regulation
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in order to override TGFß1. However, loss of this N-terminal domain does not disrupt
the ability of Cdt1(73-546) to override TGFß1 arrest (Figure 3.4H, left). Thus, the
mechanism by which Cdt1 abrogates TGFß1 cell cycle arrest in MK(Rb-) cells does not
involve dilution of Cdt1-targeted degradation machinery, but instead derives from the
function of the C-terminal MCM-binding region of Cdt1. Importantly, overexpression of
these Cdt1 alleles [particularly, Cdt1(1-435), which could not overcome TGFß1] are not
dominant negative in terms of blocking cell cycle entry, as they do not cause G1 arrest
in the absence of TGFß1 (Figure 3.4H, right). Therefore, the growth arrest that occurs in
cells expressing ectopic Cdt1(1-435) is due to TGFß1-induced effects, rather then
merely a consequence of Cdt1(1-435) expression.
Geminin accumulates on chromatin in both wildtype MK and MK(Rb-) cells
several hours after treatment with TGFß1 (Figure 3.3B), suggesting a potential inhibitory
role for Geminin in preventing MCM accumulation on chromatin in MK(Rb-) cells treated
with TGFß1. As such, elevated Cdt1 expression might be overriding TGFß1 cell cycle
arrest by sequestering endogenous Geminin in a manner that eliminates the inhibitory
effects of Geminin on MCM recruitment. However, since Cdt1(1-435) remains capable
of binding to Geminin [129], but cannot overcome TGFß1 G1-arrest (Figure 3.4H, left),
dilution of endogenous Geminin does not explain the ability of Cdt1 to override TGFß1.
Instead, our results support a model in which Cdt1 functions to abrogate TGFß1 cell
cycle arrest by alleviating a negative effect on Cdc6-dependent MCM recruitment and
CMG assembly.
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CHAPTER FOUR:
DISCUSSIONS AND FUTURE PURSUITS

Discussion

Late-G1 TGFß1 Inhibition and RbN F1 and F2 Domains
Late-G1 TGFß1 cell cycle arrest involves transcriptionally-independent
mechanisms involving physical Rb interactions with MCM [52, 116]. Smad proteins are
known to mitigate many TGFß signals via transcriptional induction or repression of
several target genes [177]. Here in Chapter 2 (Figure 2.1) however, our studies
demonstrate that Smad proteins are also required for TGFß1 growth arrest in late-G1,
despite transcription being dispensable for TGFß1 growth arrest at this time. This
suggests that there may exist a non-transcriptional role for Smads in mediating late-G1
TGFß1. However, the precise role Smads play in late-G1 arrest was not described.
Unpublished data from our lab also demonstrated that endogenous Xenopus Smad4
accumulated on chromatin (similarly to MCMs) in response to treatment with the RbN
F2 inhibitory peptide (data not shown). Smad4 protein being expressed in these extracts
is also intriguing, as transcription does not take place as they cycle. It may be that RSmad-Smad4 complexes are members of a “helicase-inhibition complex” (HIC), in
which they provide structural stability. In addition, they may recruit other factors that
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preclude helicase activation, including chromatin modifying proteins, or yet unidentified
proteins. A role for Smads in this process creates a new paradigm for Smad proteins in
general, in which their ability to mediate TGFß1 signals in late-G1 depends on a switch
from transcriptional to non-transcriptional control, coincident with the loading of MCM
hexamers. Prior to MCM loading, canonical TGFß-induced Smad effects are sufficient
to prevent hexamer formation on DNA, however once MCMs have loaded, Smads must
utilize alternate and more direct methods of preventing helicase activation in complexes
with Rb.
An intact N-terminal domain of Rb is required for tumor suppression in transgenic
mice [53], and N-terminal loss-of-function in-frame exon deletions are associated with
partially penetrant retinoblastoma [54, 239, 241-244]. Since C-terminal loss-of-function
mutations in Rb produce nearly full penetrant disease, growth-regulatory defects arising
from N-terminal in-frame exon deletions of Rb are arguably distinct in function from Cterminal deficiencies. Here, our studies establish that the N-terminus of Rb is required
for blocking the initiation and elongation of DNA replication, specifically by blocking
CMG helicase activity and DNA Pol-α recruitment.
Our findings demonstrate that inhibition of DNA replication by Rb involves
functional contributions from two domains of RbN, the F2 and the Projection/F1
domains (Figure 2.8F). Both domains are necessary and sufficient for the suppression
of DNA replication, and both domains act independently of one another and are additive
in blocking DNA initiation and elongation. The F2 domain is required to inhibit CMG
helicase activity during initiation and elongation steps, while the Projection/F1 domain
prevents proper association of DNA Pol-α and Ctf4 with replisomes. These functions are
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manifest in cell-free biochemical systems and the F1/F2 domains are required for in vivo
regulation of G1-S transit by Rb. The precise biochemical mechanisms by which the F2
and F1 elicit their effects are unknown. The Projection/F1 domain adopts a protrusion
structure [241] , which we speculate may sterically block or disrupt DNA Pol-α and Ctf4
interactions with replisomes. The CMG helicase has several activities, including ATP
hydrolysis and helicase strand separation functions, which may be disabled by
interactions with the F2 domain. Consistent with this, loss of F2 renders RbN less
efficient at binding to replicating chromatin and the Mcm7 subunit. Alternatively, the F2
domain may act indirectly, for example by preventing the association of a CMGactivating factor during initiation steps. This would seem unlikely, however, since the F2
domain is capable of inhibiting the CMG helicase even during elongation.
The partial loss of the inhibitory capacity of RbN in blocking DNA replication in
the absence of F2 domain mirrors the biological effects of the in-frame deletion in Rb
exon 7 in the partial penetrance of this allele in provoking cancer [244]. Similarly,
transgenic mice studies have shown that an in-frame N-terminal loss of a portion of Rb
(mutant RbDN1), which overlaps with almost all of Ex7/F2, also generates a partially
penetrant phenotypes in tumor incidence and in defects in embryonic development [53].
Our findings provide explanations for the partial penetrance effect of Rb alleles with
Ex7/F2 loss. For example, the F2 domain encoded by exon 7 is only required for CMG
control and the F1 domain retained in this allele would partially harness DNA replication
via polymerase control. Further, control of CMG activity may not be critical for all
biological processes involving Rb, where CMG control by Rb at G1-S may be less
necessary to harness tumorigenesis, while CMG regulation may be required of Rb for
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control of replication following DNA damage [92, 250]. Finally, there could be
compensation by the Rb family members, where p107 and p130 share significant
sequence similarity with Rb in their N-terminal regions [233, 238], and where p107 has
been shown to bind to the replicative helicase [255].
Human cancer-associated missense mutations and in-frame deletions are also
manifest in the Rb Projection/F1 domain and neighboring exons. For example, exon 6 is
mutated in prostate cancers [245] and retinoblastomas [241], and exons 4 and 5 are lost
in inherited retinoblastomas [54, 239, 243]. Such alterations might produce subtle
effects on structural features of the F1 domain that partially promote tumor
development, as proposed elsewhere [241]. Furthermore, transgenic mouse studies
have shown that a larger deletion encompassing exons 4 and 5, and part of the
Projection/F1 domain (RbDN4 mutant) has partially penetrant activity in promoting
tumor development [53]. Thus, as underscored by our studies, both the F1 and F2
domains play important roles in tumor suppression by Rb.
Much of the results obtained herein are derived from testing Rb functions in
embryonic egg extracts, and as such, a degree of caution must be reserved for our
interpretations. Although this frog extract system is a powerful tool for analyzing
metazoan DNA replication mechanisms, and currently the only practical means of
assessing in vitro cell-free biochemical functions of Rb toward higher eukaryotic DNA
replication activities, important caveats must be considered. By nature, the embryonic
system is biologically different from somatic mammalian cells, having fewer limitations
on DNA replication control than somatic cells. For example, transcription does not occur
in early embryonic cell cycles [293], Rb is not present [2, 258], and cell cycles occur
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without intervening G1/G2 phases [293]. The early embryonic S-phase is ~1/10 the
duration of somatic S-phase [294], and DNA replication is highly efficient, being able to
replicate many DNA substrates, even those in the absence of chromatin [295].
However, the basic enzymatic machinery involved in replicating DNA in these extracts is
highly conserved with both mammalian and yeast counterparts, and is subject to similar
kinase and other regulatory activities [102, 161, 266, 287, 296]. Intriguingly, it is
arguably a physiological benefit for these early embryonic S-phases not to have
endogenous Rb protein present that might limit the replicative capacity of embryonic
cells during a time of necessary rapid cell cycle division and embryonic growth.
Despite these aforementioned limitations, a remarkable number of similarities
exist between the findings obtained for Rb control of DNA replication in mammalian
somatic cells and results herein using biochemical testing with the metazoan frog
extracts. Rb has long been known to provide a negative function in regulating DNA
replication in mammalian cells [44, 52, 92, 250, 255]. Although the molecular nature of
this Rb-inhibitory function toward DNA replication has remained elusive, it has been
shown to be independent of E2F regulation and occurs during S-phase and late-G1
phase [44, 52, 92, 247, 248, 250]. Rb (by way of the RbN domain) makes direct
physical contacts with the replicative CMG helicase, in vitro and in vivo [52, 255]. An
interaction between Rb and the CMG helicase occurs in late-G1 phase [52], and
evidence suggests that Rb can target the mammalian helicase under certain conditions
during S-phase [92]. Intriguingly, this Rb-CMG interaction is required for inhibition of the
mammalian helicase in vivo in response to growth-inhibitory signals from TGFß1 [52].
Such Rb-inhibited CMG helicases that are intact but non-functional accumulate on
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chromatin in mammalian cells [52], much the same as results shown herein using frog
extracts, where RbN-inhibited CMG helicases accumulate in an inactive but intact state.
In addition, Rb mediation of TGFß1 arrest in late-G1 is also associated with failure of
the replicative polymerases to become associated with chromatin [52], similar to that
found in the extract system. The RbN domain in particular has been shown to mediate a
G1-S transit block in mammalian cells [238, 257], consistent with the RbN domain being
of primary inhibitory function toward DNA replication in the extract assays in the context
of full-length Rb. Finally, the ability of Rb phosphorylation to suppress the inhibitory
function of Rb toward DNA replication in vitro is consistent with findings in mammalian
cells where Rb inhibits S-phase progression following dephosphorylation by PP2A [92].
In the latter situation, dephosphorylated Rb becomes associated with regions of
chromosomes where MCMs/origins reside and DNA replication is co-suppressed [92].
These consistencies strongly suggest that the biochemical analyses of Rb/RbN in the
frog extract system are likely of physiological relevance to the mechanisms used by Rb
in mammalian cells to control DNA replication.
It is important to keep in mind that the temporal interaction of Rb with the
helicase or other aspects of the replication machinery in mammalian cells is likely more
complex than that illustrated herein using biochemical assays with embryonic extracts.
For example, it is possible that Rb interacts with somatic helicases in G1-phase prior to
its heightened late-G1 phosphorylation, and that some phosphorylation on Rb may
occur without disrupting pre-formed Rb-CMG interactions until further sites are modified.
Indeed, progressive phosphorylation on specific Rb residues is known to regulate E2F
interactions with Rb, some of which prevent E2F binding while others disrupt pre-bound
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E2F [50]. Our approach herein necessarily involved testing pre-phosphorylated
(mimicked) Rb derivatives, overexpressed transiently or directly added to replicative
machinery as it formed, and thus our methods cannot distinguish these possibilities.
Caveats appreciated, our work provides an initial framework for understanding the
complexities by which Rb negatively regulates metazoan CMG helicases, and has
elucidated two functional domains (F1 and F2) within the Rb amino-terminal region that
mediate Rb control over DNA replication. While the F1 and F2 domains are also likely
responsible for TGFß1 late-G1 arrest, this is yet to be determined. It would be intriguing
to discover if Rb/RbN F2 and F1 deletion constructs used above in Chapter 2 could
rescue TGFß1 growth arrest in late-G1, versus wildtype Rb, in cells lacking Rb where
late-G1 TGFß1 arrest is normally ineffective [52].

Early-G1 TGFß1 Arrest in the Absence of Rb
The absence of Rb renders cells severely compromised for their molecular
responses to TGFß1-induced cell cycle arrest. Under such conditions, the expression of
c-Myc is not inhibited, nor are the activities of CyclinE-Cdk2 and Cdc7-Dbf4 kinases. In
addition, all of the subunits of the MCM heterohexamer are expressed, unlike in normal
cells where all are suppressed at the protein abundance level by TGFß1 [52]. The
absence of Rb also removes an inhibitory function utilized by TGFß1 in late-G1 to
suppress CMG helicase activation, should helicases be assembled [52]. Despite these
significant limitations, TGFß1 remains potently capable of blocking G1 progression
when added to cells in the early-G1 interval. We demonstrate here that the mechanism
mediating TGFß1 arrest under these conditions involves an inability to efficiently recruit
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the MCM complex to chromatin via inhibition of Cdc6 phosphorylation (minimally at
serine 54), and accordingly, failure to load the MCM hexamer onto DNA. This effect of
TGFß1 on MCM recruitment/loading prevents CMG helicase assembly and S-phase
entry even though major players in the MCM/CMG assembly and activation process
(Myc, CyclinE-Cdk2, and Cdc7-Dfb4) are present and functional [266, 280, 297].
It is intriguing that TGFß1 blocks Cdc6 serine-54 phosphorylation, while the CDK
implicated in modifying this site, CyclinE-Cdk2 [144-146], remains active in these cells
(Figure 3.2B, bottom). Several potential explanations exist for this phenomenon. TGFß1
may block the activity of another kinase, not studied herein, which is responsible for
phosphorylating Cdc6 serine 54. Better insight comes from studies that demonstrate a
kinase-independent function for the CyclinE-Cdk2 complex in facilitating MCM loading
[147, 298, 299]. Using Xenopus extracts, it was found that a direct interaction between a
hydrophobic MRAIL motif of cyclin E and RXL (Cy) motifs in Cdc6, which is detected
upstream of MCM recruitment, is essential for CyclinE-Cdk2 chromatin localization,
Cdc6 phosphorylation, and initiation of DNA replication [147]. These RXL motifs are in
close proximity to N-terminal Cdc6 phosphorylation sites [147]. Importantly, CDK activity
by CyclinE-Cdk2 was not required for Cdc6-CyclinE-Cdk2 complex formation, as
addition of the Cdk inhibitor roscovitine did not affect Cyclin E chromatin recruitment
[147]. We hypothesize that TGFß1 perturbs Cdc6 phosphorylation by blocking Cdc6CyclinE interactions on chromatin, which is sufficient to prevent MCM loading onto DNA,
despite CyclinE-Cdk2 being catalytically active [147]. Consistent with this, TGFß1 does
not inhibit CyclinE-Cdk2 kinase activity in Rb lacking cells (Figure 3.2B, bottom), but
Cdc6 phosphorylation remains blocked (Figure 3.3C). Cyclin E interactions with Cdt1
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have also been implicated in loading MCMs, independent of the kinase activity of Cyclin
E [298]. It was demonstrated that kinase-deficient Cyclin E mutants were capable of
restoring MCM loading and S phase entry in G0 Cyclin E-null cells, but cells lacking
Cyclin E failed to load MCMs onto Cdt1-bound chromatin [298] (Figure 3.3A, right).
Therefore, the details of the interaction between CyclinE-Cdk2 and preRC proteins that
facilitate MCM loading may be biochemically distinct from a kinase-substrate interaction,
which may then lead to subsequent Cdc6 phosphorylation (perhaps on serine 54) that
regulates its effect on future licensing dynamics [144, 147]. It would be interesting to
explore early-G1 TGFß1-mediated effects on CyclinE-Cdc6 or –Cdt1 interactions in the
MK(Rb-) cells. Using TGFß1 in this way will facilitate the elucidation of these and other
molecular details that normally contribute to preRC assembly, and that are perturbed
my TGFß1 signals.
TGFß1 treatment of MK(Rb-) cells suppresses the recruitment of all six MCM
subunits. However, It could be argued that Mcm6 is particularly suppressed under these
conditions (Figure 3.3A, middle). Yeast studies have shown that Mcm6 is unique among
the MCM subunits in that it contains an auto-inhibitory domain that limits MCM
recruitment and loading [127]. Cdt1 suppresses this auto-inhibitory function during the
recruitment process by binding to Mcm6 [127]. The interaction between Mcm6 and Cdt1
occurs through the C-terminal Mcm6-binding domain of Cdt1 [128, 288, 300, 301], and
perturbation of the Cdt1-Mcm6 interaction prevents MCM recruitment in yeast [127]. In
mammalian cells, perturbation of the Cdt1-Mcm6 interaction also causes problems with
MCM assembly, and inhibits cell proliferation and DNA replication [128].
We show here that TGFß1 growth arrest is associated with an absence of Cdt1104

MCM interactions on chromatin, whereby Cdt1 is present, but MCMs are not recruited to
the chromatin. TGFß1 inhibitory signals may also take advantage of the auto-inhibitory
domain within Mcm6 to block the MCM recruitment process, and interactions with Cdt1
block this mechanism. In addition, phospho-Cdc6 (at serine 54) may facilitate Cdt1MCM interactions on chromatin that preclude the Mcm6 auto-inhibitory domain,
facilitating MCM loading. TGFß1-induced inhibition of Cdc6 phosphorylation may
contribute to this mechanism, however it is not conclusive from this work. However,
consistent with this idea, perturbation of Cdc6 function is known to stabilize Cdt1 on
chromatin with diminished MCM interactions (Figure 3.3A, right) [124]. In additional
support of this model, overexpression of Cdt1 abrogates the negative effects of TGFß1
and restores S-phase entry. Loss of the MCM- (Mcm6-)- binding domain from Cdt1
prevents Cdt1 from abrogating TGFß1 cell cycle arrest, consistent with yeast studies
showing that mutation of the C-terminus of Cdt1 prevents Cdt1 from restoring MCM
assembly [127]. Although the biochemical and molecular mechanisms mediating the
interaction between Cdt1 and Mcm6, and specific Cdc6 contributions to such
interaction, remain poorly understood in yeast and mammalian cells, future studies
using TGFß1 as a tool will enable a better understanding of this process.
The ability of Cdt1 to override TGFß1 in Rb-lacking cells has implications for
human tumorigenesis. Cancers often lose sensitivity to the inhibitory effects of TGFß1
via disruption of pathways mediating TGFß1 arrest. Cdt1 is oncogenic and
overexpressed in several human cancers, including lung and colon carcinomas,
melanomas, and some leukemias and lymphomas [302-304]. Cdt1 oncogenicity is
known to derive from its ability to cause re-replication and genomic instability [303, 305].
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Our results provide yet another explanation for Cdt1 oncogenicity, whereby elevated
Cdt1 can disrupt the TGFß1 pathway and promote cell cycle progression by
reestablishing MCM assembly and CMG function. Although it was not tested in these
studies, Cdc6 overexpression may also override TGFß1 in the absence of these
mediators. Deregulating Cdc6 may force interactions that are perturbed by a TGFß1
block of Cdc6 phosphorylation. This would be consistent with results from many of the
above studies, where Cdc6 was also capable of causing re-replication in addition to
Cdt1 [303, 305].

Conclusions for TGFß1 Cell Cycle Arrest, Implications, and Future Pursuits

At its core, this dissertation is an exploration of TGFß1 cell cycle arrest
mechanisms that are utilized from early-G1 phase, and through to late-G1, just before
the G1-S transition. While there are instances that are not fully understood in which
TGFß1 growth arrest occurs in the absence of its common effectors [217, 231, 232],
retention of TGFß1-induced negative effects on CMG helicase assembly and/or
activation provides explanations for all of these cases. In fact, modulating dynamics of
the helicase appears to be the ultimate goal of TGFß1 to elicit cell cycle arrest. The
precise mechanisms that TGFß1 has at its disposal to inhibit the DNA helicase
dynamics is temporally-dependent, and additionally depends on the presence of Rb
protein. In wildtype cells (containing a functional Rb), early-G1 TGFß1 blocks the
protein expression of the MCMs, and therefore no CMG can even form (Figure 3.1E,
top) [52]. This effect also occurs coincident with canonical mechanisms for TGFß1
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growth arrest, including c-Myc suppression, CyclinE-Cdk2 kinase inhibition, and
suppression of Rb hyperphosphorylation (Figure 3.2A, top; Figure 3.2B, top; [52],
respectively). As wildtype cells transit to late-G1 (by which MCMs have already
assembled on chromatin), the presence of Rb protein, and likely the RbN F1 and F2
domains, becomes critically required for TGFß1 growth arrest. This TGFß1-induced
tumor suppressive function of Rb (and its RbN domain) is derived from direct
interactions of Rb and the MCM complex that precludes CMG activation and replisome
formation in vitro, resulting in the inhibition of DNA replication [52] (Figure 2.7A&B)
(Figure 2.3B). As expected, cells lacking sufficient Rb protein expression, are no longer
sensitive to TGFß1 in late-G1. Surprisingly, TGFß1 retains the ability to inhibit these
same cells lacking Rb in early-G1 [52]. In stark contrast to wildtype cells, TGFß1 earlyG1 arrest in Rb-deficient cells does not occur along with c-Myc suppression, inhibition of
CyclineE-Cdk2 kinase activity, or even a block in MCM protein expression (Figure 3.2A,
bottom; Figure 3.2B, bottom; Figure 3.1E, bottom, respectively). While Rb lacking cells
have lost TGFß1-associated control over each of these molecular mechanisms, TGFß1
growth arrest still occurs. Again, regulation of the CMG helicase is the answer. TGFß1
early-G1 treatment in cells lacking Rb leads to the inhibition of MCM hexamer
recruitment and loading, manifest at a Cdc6-Cdt1 recruitment and loading step. In these
cells with no Rb, it is not until this last mechanism for TGFß1-dependent helicase
control is overcome by Cdt1 overexpression that cells become insensitive to TGFß1
throughout all of G1. Together, these data strongly indicate that the main underlying
explanation for TGFß1 growth arrest sensitivity is derived primarily from the ability to
inhibit formation and/or activation of the CMG helicase. The implication of this work is
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that cancer cells that have become insensitive to TGFß1 growth arrest in vitro and in
vivo have likely also lost control over CMG assembly and activation processes. This
would argue that targeting CMG functionality may present new therapeutic avenues for
tumors in which TGFß1 sensitivity is lost, or Rb is deleted, and/or Cdt1 is
overexpressed.
Additional aspects of MCM biology also argue that CMG helicases would be
effective targets for cancer treatment. Eukaryotic cells license more origins than are
necessary for a normal S phase by loading extra MCM complexes [142]. Four to five
MCM hexamers exist per average mammalian replicon, although initiation from two
heterohexameric MCM complexes is sufficient to copy a given replicon. This amounts to
approximately 2 extra MCM complexes in a given replicon, both with the potential to
form active helicases [111]. These dormant or residual MCM complexes are suppressed
normally by S phase kinase activity, but become functional upon replication fork stalling
following treatment with replication inhibitors such as hydroxyurea (HU), a
ribonucleotide reductase inhibitor, or aphidicolin, a DNA polymerase inhibitor [151]. This
stress-induced activation of residual origins following drug treatment recovers DNA
replication rates, but reduction of dormant MCMs using siRNA results in an inability to
recover DNA synthesis during replicative stress, imposed for example by fork stalling
drugs [151]. The need for DNA replication to be able to recover from S phase stresses
is an explanation why cells license two to three-fold more MCMs than are required, as
well as why MCMs are not predominantly detected at replication foci [113].
Other studies have demonstrated that residual MCMs are also critical for
traversing a normal unperturbed S phase, and for suppressing genomic instability and
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tumor formation [142]. Therefore, the presence of back-up MCM complexes represents
a common mechanism for tumor suppression. Yet, targeting MCMs with drugs that
effectively reduce the dormant MCM complexes beyond what is tolerable may be
detrimental to normal cells, in addition to tumor cells. However, this is likely an issue
that could be addressed by calibrating the dosing of an MCM-targeting drug. In addition,
it has been shown that cancer cells are more sensitive to a reduction in residual MCM
complexes, versus normal cells, and that this reduction chemosensitizes cancer cells to
clinically-relevant drugs, including gemcitabine and 5-fluorouracil (5-FU) [306].
Together, these data suggest that tumor cells that have diminished residual MCM
complexes would be uniquely sensitive to an MCM (CMG) inhibitor. In truth, this quality
may be manifest in a wide variety of tumors (if not all), where common oncogenic
drivers such as Cyclin E and c-Myc (thought to be overexpressed in 70% of human
tumors), or a loss of tumor suppressive RbN (or TGFß1) function, can effectively lead to
a reduction of MCM back-ups at origins [96, 153].
These aspects of MCM cancer biology, as well as their critical importance for
mediating TGFß1 arrest throughout all of G1, illuminates the CMG replicative helicase
as a promising chemotherapeutic target [307]. While there exist some molecules that
display some helicase inhibition in vitro toward SV-40 T antigen, such as
fluoroquinolones like ciprofloxacin, these studies are in their infancy, and provide no
means to discriminate between SV40 T-antigen versus CMG helicase inhibition as
structure-activity relationships for these compounds is poorly understood. This
dissertation not only contributes to the idea that the CMG is a worthy drug target for
cancer treatment, but provides a framework for elucidating exactly how the CMG could
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be targeted (Chapter 2). We have demonstrated that the F2 domain of Rb (RbN), or Rb
exon 7, inhibits DNA replication by specifically blocking CMG helicase activation (Figure
2.3B&C). This RbN F2 peptide represents the first potential inhibitor of the human
helicase in existence, and more importantly, sets up a base upon which helicase
inhibitors biochemically mimicking its function could be developed. As it stands, F2 is 40
aa in length, which is slightly too large to base the development of small molecule
inhibitors on. However, the Xenopus in vitro replication assay utilized in Chapter 2
represents an assay that could be used to determine the smallest active component of
F2. In addition, elucidating the crystal structure of such a reduced peptide interacting
with the MCM complex would provide invaluable structure-activity information. One
group has purified the human CMG helicase using a baculovirus expression system,
and has established in vitro human helicase assays [267, 277]. We have already begun
attempting to recapitulate this system in our lab, to serve as an alternate means by
which to test RbN F2-derivative peptides for their ability to inhibit the helicase, but in a
more direct way than Xenpous extracts. In addition, such an assay, if scaled up, could
be utilized to screen small molecule libraries in high-throughput screens (HTS).
Applying a fluorometric readout to these types of studies, involving the measurement of
helicase-derived ATPase activity, also represents an approach to robustly quantify the
efficacy of a potential helicase inhibitor.
Another potentially beneficial system that could be adopted to discern the active
component of F2 and its effects is the TAT peptide-tagging approach [308]. Peptides
tagged with these sequences along with an NLS, are passively taken up by cells, and
move to the nucleus via their NLS sequence. Once in the nucleus, TAT-tagged peptides
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have been shown to effect predicted pathways in vivo, and their uptake can occur within
minutes of exposure to cells [308]. Mammalian cell colony forming assays utilizing TATNLS-tagged RbN F2 domain-derivatives is a potential means by which F2 peptides may
be tested for their ability to block proliferation, or to effect expected molecular events
that would occur following helicase activation (i.e. RPA suppression from chromatin). In
addition, the rapid uptake of TAT-tagged peptides may facilitate studies in which precise
temporal effects of TAT-tagged peptides can be measured (similarly to synchronization
experiments utilizing TGFß1). It would be interesting to see if a TAT-tagged F2 peptide
could inhibit cell cycle progression specifically in late-G1, akin to TGFß1-induced Rb
helicase inhibition. Additionally, whether or not such a peptide could inhibit cell cycle
entry in cells lacking Rb is also of interest.
The work herein is proof of principle that several of these approaches should be
honed to develop a potent inhibitor of CMG helicases (or replisomes via RbN F1
information), as they would represent a novel paradigm for cancer treatment. Such a
molecule(s) could serve a great deal of cancer patients, where deregulation of MCM
(CMG) dynamics in a variety of molecular fashions (some elucidated herein) can
promote tumor formation. As MCM perturbation also increases the efficacy of current
chemotherapies, combinational regimens including an MCM (CMG) inhibitor could also
reduce toxicity that is associated with these compounds.
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